

## INDEX

Note: Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.  
Clinical trials are listed by their acronyms.

- A1C. See *Glycosylated hemoglobin (A1C)*.
- Abdominal pain, in diabetic ketoacidosis, 282t  
See also *Gastrointestinal symptoms*.
- Acanthosis nigricans  
diabetes secondary to, 30t  
in dysmetabolic syndrome X, 45t
- Acarbose (Precose), 76t, 135-138  
action mechanism, 135  
combination therapy, 136, 144  
dosing, 76t, 136, 137t  
glycemic control with, 135-136  
hypoglycemia, safety for, 135  
PPG levels and, 135  
prescribing considerations, 136-137, 137t  
side effects, 135, 136  
in Stop-NIDDM, 338t, 341
- ACCORD trial, 69-70, 71, 71, 72
- Accu-Chek blood glucose meters, 258t
- ACE inhibitors. See *Angiotensin-converting enzyme (ACE) inhibitors*.
- Acetaminophen, for painful diabetic neuropathies, 323
- Acetohexamide (Dymelor), 77t, 138
- Acetone breath, in diabetic ketoacidosis, 282t
- Acidosis. See also *Diabetic ketoacidosis (DKA)*.  
in diabetic ketoacidosis, 281-282  
MET therapy and, 81-82
- Acquired factors in type 2 diabetes, 22, 23, 24-25
- Acromegaly, diabetes secondary to, 30t
- ACT-NOW (Actos Now for Prevention of Diabetes trial), 338t, 343-344, 343
- Actoplus Met (pioglitazone/metformin), 78t, 99. See also *Metformin*;  
*Pioglitazone*.  
glycemic control with, 99  
prescribing considerations, 97-98
- Actos Now for Prevention of Diabetes (ACT-NOW) trial, 338t, 343-344, 343
- Actos. See *Pioglitazone*.
- Acupuncture, for painful diabetic neuropathies, 322, 323
- Acura blood glucose meter, 258t
- Acute complications. See *Complications of diabetes, acute*.
- ADA. See *American Diabetes Association*.
- Adolescents, type 2 diabetes in, 35
- Advance Intuition monitoring system, 258t
- ADVANCE trial, 69-70, 71-72
- Advocate blood glucose meters, 258t
- African Americans. See also *Race/ethnicity*.  
incidence of diabetes in, 16  
prevalence of diabetes in, 13, 15, 32, 37
- Age  
incidence of diabetes and, 16, 18, 19  
of onset  
late-onset type 1 diabetes (LADA), 181  
maturity-onset diabetes of the young, 35  
type 1 diabetes, 29, 30t  
type 2 diabetes, 16, 17, 30t, 32, 35  
prevalence of diabetes and, 13, 14  
as risk factor for CHD, 41  
as risk factor for diabetes, 13, 22, 23, 34, 38  
screening and, 345  
undiagnosed diabetes and, 14
- Alanine aminotransferase (ALT), 98, 283t
- Alaskan natives, prevalence of diabetes in, 13, 15
- Alcohol use/intake, 52t, 57  
glycemic testing, false highs with, 252  
SFUs and, 57, 139  
sugar alcohols, 56
- Aldosteronism, diabetes secondary to, 30t
- Algorithm  
for insulin therapy, 170, 171  
for treatment, 243-245, 246-247
- Allergy to insulin, 163
- ALLHAT, 346t
- $\alpha$ -Blockers, 300t, 301t, 303  
in treatment of diabetic nephropathy, 320
- $\alpha$ -Cell hormone. See *Glucagon*.
- Alpha-glucosidase inhibitors, 76t, 135-138. See also *Acarbose*; *Miglitol*.  
action mechanism, 135  
in algorithm for treatment, 246  
combination therapy, 81, 136, 246  
dosing, 76t, 136, 137t  
side effects, 135, 138
- ALT. See *Alanine aminotransferase*.
- Amaryl. See *Glimepiride*.
- American Association of Clinical Endocrinologists (AACE)  
dysmetabolic syndrome criteria, 45, 45t  
management goals and targets, 245  
PPG/glycemic control goals, 65, 66t, 245
- American Association of Diabetes Educators (AADE), 351
- American Association of Kidney Patients, Inc. (AAKP), 351
- American College of Cardiology, sildenafil recommendations, 328-329
- American Diabetes Association (ADA), 351-352  
consensus statements, 75, 99, 245  
criteria for diabetes diagnosis, 38t  
on dyslipidemia treatment priorities, 308, 309t  
on screening for diabetes, 345  
targets/goals for glycemic control, 41, 66t, 245

American Dietetic Association, 352  
 American Heart Association, 353  
 American Indians  
   incidence of diabetes in, 16  
   Indian Health Services (IHS), 353-354  
   prevalence of diabetes in, 13, 15, 32  
   risk of diabetes in, 37  
 Amitriptyline, for painful diabetic neuropathies, 322, 323  
 Amoxicillin trihydrate, 325  
 Amputation, 330  
   end points in PROactive study, 93-97, 95  
   end points in Steno-2 Trial, 70  
   foot care for prevention of, 330-331, 332t  
 Amylin, 230-232  
   action mechanisms, 230-232, 232  
   analogue (pramlintide). See *Pramlintide therapy*.  
   cosecretion with insulin, 230, 231  
   deficiency in diabetes, 230, 231, 233  
   GLP-1 and, 191  
 Amyotrophy, diabetic, 321t, 324  
 Angiotensin-converting enzyme (ACE) inhibitors, 44-45, 299-302, 345  
   benefits of, 301t  
   complications of, 300t  
   potassium and, 56-57, 302  
   in treatment of diabetic nephropathy, 318, 319, 320  
   in treatment of metabolic syndrome, 44-45  
   in treatment of microalbuminuria, 45, 302  
   trials of, 345, 346t  
     Steno-2 Trial, 69  
     UKPDS, 302  
 Angiotensin II receptor blockers (ARBs), 44-45, 299, 303, 345  
   benefits of, 301t  
   complications of, 300t  
   in treatment of diabetic nephropathy, 318, 319, 320  
   in treatment of metabolic syndrome, 44-45  
   in treatment of microalbuminuria, 45  
   trials of, 345, 346t  
     NAVIGATOR trial, 344  
     Steno-2 Trial, 69  
 Anorexia  
   in diabetic ketoacidosis, 282t  
   in diabetic neuropathy, 322  
   metformin and, 81  
   pramlintide and, 233, 240  
 Antibiotics, 294-295t, 325  
 Antibodies  
   to exenatide, 198  
   to GAD, 36, 161, 181  
   to insulin, 29, 163, 170  
   to islet cells, 29, 161  
 Antifungal therapy, 294t  
 Antihypertensive drugs, 21t, 299-304, 345, 346t.  
   See also *specific agents*.  
   clinical trials involving, 346t  
   potential benefits of, 301t, 345, 346t  
   potential complications of, 300t  
   secondary diabetes associated with, 30t  
   side effects with, 299, 300t  
   in treatment of diabetic nephropathy, 318, 319, 320  
 Anti-inflammatory agents, for diabetic neuropathies, 321  
 Antioxidant supplements, 52t, 57, 319  
 Apidra (glulisine), 162, 182  
   regimens for, 169t  
   time course of action, 164-165, 166t, 168  
 Appetite  
   GLP-1 reduction of, 192-193  
   pramlintide reduction of, 231, 232  
 ARBs. See *Angiotensin II receptor blockers (ARBs)*.  
 Argon laser photocoagulation, 316-317  
 Asian/Asian-American patients, 162, 345. See also *Race/ethnicity*.  
 Aspart (Novolog), 162, 182. See also *Novolog*; *Novolog Mix*.  
   time course of action, 164-165, 166t  
 Aspirin  
   glycemic testing, false highs with, 252  
   in Steno-2 Trial, 69  
   in treatment of metabolic syndrome, 45  
   in treatment of painful diabetic neuropathies, 322, 323  
 Assessment of treatment regimen, 249-278  
   blood glucose meters, 258t-264t  
   continuous glucose monitoring systems, 273-277  
   fructosamine measurement, 252-253, 253  
   glycated hemoglobin measurement, 251-252  
   key parameters, 249  
   metabolic goals, 250t  
   other glycated proteins, 252-253, 253  
   plasma glucose concentrations, 249-251  
   self-monitoring of blood glucose, 253-277, 258t-264t.  
     See also *Self-monitoring of blood glucose (SMBG)*.  
 Asymptomatic diabetes, 32-33, 37  
 Atazanavir, 125  
 Atenolol, in UKPDS, 302, 303  
 Atherosclerosis  
   antioxidant supplements and, 57  
   dyslipidemia and, 304  
   type 2 diabetes and, 63  
 Atorvastatin, 309, 310t  
 Autoimmunity, 29, 162  
 Avandamet (rosiglitazone/metformin), 78t, 84  
 Avandaryl (rosiglitazone/glimepiride), 78t, 84  
 Avandia. See *Rosiglitazone*.

- B-type natriuretic peptide (BNP), 100
- Bacteriuria, 294t
- β-Blockers, 300t, 301t, 303  
 impotence and, 327  
 secondary diabetes and, 30t  
 in Steno-2 Trial, 69  
 in UKPDS, 302
- β-Cell  
 calcium influx into, 145  
 destruction, in type 1 diabetes, 29  
 exhaustion, 73, 140, 161  
 failure, 23, 180, 230  
 function  
 compensation for insulin resistance, 22  
 decreased, in type 2 diabetes, 23  
 exenatide and, 195-196, 199-200  
 GLP-1 and, 191, 194  
 HOMA-B assessment of, 108, 195-196  
 insulin therapy and, 230  
 linagliptin and, 128  
 liraglutide and, 206  
 nateglinide and, 145  
 saxagliptin and, 119  
 SFUs and, 140  
 sitagliptin and, 108, 109  
 genes, 194  
 GLP-1 receptors on, 191  
 granules, 230  
 hormones. *See Amylin; Insulin.*  
 potassium channel regulation in, 142
- Bethanechol, in treatment of neurogenic bladder, 326
- Bicarbonate treatment  
 for diabetic ketoacidosis, 284, 286  
 for HHNS, 290
- Biguanide. *See Metformin.*
- Bile acid sequestrants (colesevelam; Welchol), 76t, 148-152, 311.  
*See also Colesevelam (Welchol).*  
 action mechanisms, 148  
 adverse events, 151-152, 311  
 clinical efficacy, 148-151, 150-151  
 in combination therapy, 149-151  
 contraindications, 152  
 dosage, 76t, 152  
 hyperlipidemia, use for, 148  
 other than colesevelam, 311  
 prescribing considerations, 152  
 in treatment of diabetic dyslipidemia, 309, 309t, 310t, 311
- Blacks. *See African Americans.*
- Bleeding, A1C and HbA<sub>1c</sub> testing and, 251
- Blindness, diabetes and, 313
- Blood glucose meters, 258t-264t, 272  
 contact information for manufacturers, 266t-267t
- Blood glucose monitoring. *See Glucose monitoring.*
- Blood pressure. *See also Hypertension.*  
 cardiovascular risk assessment and, 249  
 decrease with ramipril, 342  
 diet and, 49  
 hypertension, 299-304  
 hypotension, orthostatic, 326  
 in metabolic syndrome, 44t  
 monitoring, 249  
 target/goal levels, 299  
 treatment of, in Steno-2 Trial, 69
- Bloodletting devices, advances in, 272-273
- BlucaGen HypoKit, 292
- Blurred vision, 37, 291, 296, 316t
- Body fat, distribution of, 32, 34. *See also Obesity.*  
 pioglitazone and, 90  
 rosiglitazone and, 342
- Body mass index (BMI), 37, 339, 345
- Body weight. *See Weight.*
- Brainstem hemorrhage, 281
- Breeze 2 blood glucose meter, 258t
- Bromocriptine mesylate (Cycloset), 76t, 152-154  
 action mechanism, 75, 152-153  
 adverse events, 153-154, 155  
 clinical efficacy, 153  
 combination therapy  
 with metformin, 246  
 with SFU, 153, 154  
 contraindications/cautions, 154  
 Cycloset Safety Trial, 154, 155  
 dosage, 76t, 154  
 FDA approval of, 152, 153  
 glycemic control with, 152, 153  
 hypoglycemia and, 154  
 prescribing considerations, 154
- Byetta. *See Exenatide.*
- C-peptide levels, 119, 141, 162
- C-reactive protein (CRP), 93, 94
- Cachexia syndrome, 322
- Calcium channel blockers (CCBs), 300t, 301t, 303-304  
 in Steno-2 Trial, 69  
 in treatment of diabetic nephropathy, 320
- Calcium supplements, 52t
- Caloric intake, 49, 51, 305, 308t. *See also Diet; Nutrition; Weight.*  
 “spread the calories,” 135
- Caloric requirements, adult, 51
- Candesartan, 303, 320
- Candesartan and Lisinopril Microalbuminuria study, 303
- Candida* skin infection, 294t
- CAPP (Captopril Prevention Project), 346t

Capsaicin, topical, for painful neuropathies, 322, 323  
 Captopril, 302, 346t  
 Captopril Prevention Project (CAPPP), 346t  
 Carbamazepine, 322  
 Carbohydrates, 54-55. See also *Diet; Nutrition*.  
   dietary intake of, 52t, 54-55, 308t  
   in treatment of hypoglycemia, 291-292  
 Carbuncles, 294t  
 Cardiovascular reflexes, impaired, in diabetic neuropathy, 321t, 326  
 Cardiovascular risk, 40-44, 63, 298  
   alcohol intake and, 52t  
   antihypertensive agents and, 300t, 301t, 302, 303-304  
   assessment of, 40-44, 249  
   bromocriptine mesylate and, 154, 155  
   calcium channel blockers and, 303-304  
   diabetes as risk equivalent, 41  
   dietary guidelines for, 54  
   dyslipidemia and, 40-44, 304-305  
   exercise and, 59  
   major adverse cardiac events (MACE), 95  
   metformin and, 82  
   pioglitazone and, 93-97, 95  
   reduced  
     in ACCORD and ADVANCE trials, 69-70, 71, 71  
     with pioglitazone, 93, 95  
     in PROactive Study, 93-97, 95, 101  
     in Steno-2 Trial, 69, 70  
     in UKPDS, 67-69, 67t  
   rosiglitazone and, 84, 342  
   thiazolidinediones (TZDs) and, 84, 95, 99, 100-101, 100t  
 Cardiovascular status, monitoring in HHNS, 289  
 CARDS (atorvastatin) trial, 310t  
 CARE (Cholesterol and Recurrent Events) study, 310t  
 Carpal tunnel syndrome, 324  
 Cataracts, antioxidant supplements and, 57  
 CCBs. See *Calcium channel blockers*.  
 CCK-8, gastric emptying and, 233  
 CDC. See *Centers for Disease Control*.  
 Cellulitis, 294t  
 Centers for Disease Control (CDC), 353  
   metabolic/dysmetabolic syndrome, code for, 45  
 Central nervous system, glucose homeostasis and, 230, 232  
 Central obesity. See *Obesity, central*.  
 Cerebrovascular accident, 281  
 Cerebrovascular disease, 298. See also *Macrovascular disease*.  
 CHD. See *Coronary heart disease*.  
 CHF (congestive heart failure)  
   metformin and, 82  
   TZDs and, 99-100, 100t  
 Children, type 2 diabetes in, 35  
 Chlorpropamide (Diabinese), 77t, 138  
   hypoglycemia with, 139  
   reaction to alcohol with, 139  
 Cholecystokinin, bile acid sequestrants and, 155  
 Cholestasis, 140  
 Cholesterol and Recurrent Events (CARE) study, 310t  
 Cholesterol levels, 304-312, 306t  
   calculating, formula for, 305  
   dietary guidelines for, 54  
   HDL. See *High-density lipoprotein (HDL)*.  
   lipid-lowering agents for, 308-312, 309t, 310t  
   risk levels for adult diabetic patients, 37  
   target/goal levels, 250t, 305, 306t, 307t, 308t  
   treatment recommendations based on, 305-308, 307t  
 Chromium supplementation, 56  
 Cialis (tadalafil), 327-329, 328t  
 Cimetidine, sildenafil cautions with, 329  
 Ciprofloxacin HCl, 325  
 Cisapride, 325  
 Clarithromycin, 125  
 Classification of diabetes mellitus, 29-36, 30t-31t  
   gestational (GDM), 30t, 34-35  
   impaired fasting glucose (IFG), 33t, 34  
   impaired glucose tolerance (IGT), 33-34, 33t  
   other types of, 30t-31t, 33  
   problems with, 35-36  
   type 1, 29-32, 30t  
   type 2, 30t, 32-33  
 Clinical trials. See *Trials and studies; specific trials by name*.  
 Clonidine  
   for diabetic diarrhea, 325  
   for diabetic nephropathy, 320  
 Codefree blood glucose meter, 258t  
 Colesevelam (Welchol), 76t, 148-152, 311. See also *Bile acid sequestrants*.  
   action mechanisms, 148  
   adverse events, 151-152, 311  
   in algorithm for treatment, 246  
   approved for glycemic control in T2D, 311  
   clinical efficacy, 148-151, 150-151  
   combination therapy  
     with HMG-CoA inhibitor (statin), 148, 311  
     with metformin, 81, 149, 246  
     with SFU, 149-151, 151  
   contraindications, 152  
   dosage, 76t, 152  
   dyslipidemia treatment with, 148, 311  
   formulations, 152  
   oral-suspension, 152, 311  
   glycemic control with, 148-151, 150-151, 311  
   hypoglycemia and, 151

- Colesevelam (Welchol) (*continued*)  
 indications for, 148, 311  
 prescribing considerations, 152  
 tolerability, 311
- Colestid, 311
- Coma, diabetic, infection and, 293
- Combination therapy. See *specific agents*.
- Complications of diabetes, 279-335  
 acute, 279-296  
   diabetic ketoacidosis (DKA), 279-286  
   hyperosmolar hyperglycemic nonketotic syndrome (HHNS), 286-290  
   hypoglycemia, 279, 290-293  
   infection, 293, 294t-295t  
   quality of life issues, 279, 296  
 delay/prevention of, with glycemic control, 245, 297-298  
 early detection and treatment, reduction with, 25-26, 33, 297-298  
 long-term, 297-335  
   diabetic nephropathy, 317-321  
   diabetic neuropathy, 321-330  
   diabetic retinopathy, 313-317  
   dyslipidemia, 304-312  
   foot disorders, 330-331  
   hypertension, 299-304  
   macrovascular disease, 298-312  
   microvascular complications, 312-330  
   metabolic, 279-293  
   monitoring/tests for, 249  
   postprandial hyperglycemia and, 65
- Computer software, use in SMBG, 258t-264t, 272
- Confusion  
 HHNS and, 287  
 hypoglycemia and, 291
- Congestive heart failure (CHF). See *CHF*.
- Constipation, 151, 311
- Continuous glucose monitoring systems, 273-277
- Contour blood glucose meters, 259t
- Control blood glucose meter, 259t
- Coronary artery disease, 298. See also *Macrovascular disease*.  
 bypass grafting (CABG), in Steno-2 Trial, 70  
 reduction with type 2 diabetes treatment, 66
- Coronary heart disease (CHD)  
 dysmetabolic syndrome X and, 45t  
 risk factors for, 41, 44
- Cost-effectiveness of screening, 337, 345
- Cranial mononeuropathies, 324
- Creatinine clearance (CrCl)  
 in diabetic ketoacidosis, 283t  
 in diabetic nephropathy, 317, 318, 319  
 metformin and, 82  
 sitagliptin and, 112-113, 114
- Creatinine phosphokinase (CPK), 311-312
- CRP. See *C-reactive protein (CRP)*.
- Cushing's syndrome, diabetes secondary to, 30t
- Cutaneous infections, 294t
- Cycloset Safety Trial, 154, 155
- Cycloset. See *Bromocriptine mesylate*.
- Cytochrome P-450 enzymes  
 rosiglitazone and, 84  
 saxagliptin and, 125
- Da Qing IGT and Diabetes Study, 337-339, 338t
- DAIS (fenofibrate) trial, 310t
- DCCT (Diabetes Control and Complications Trial), 66, 297-298  
 glycemic assessment by SMBG, 254-255  
 value of improved glycemic therapy, 245, 297-298, 319
- Dehydration  
 in diabetic ketoacidosis, 280, 282t, 284  
 in HHNS, 287, 289
- Detemir (Levemir), 162, 184-185  
 in basal bolus insulin strategy, 179-180  
 dosage/regimens, 179, 184  
 switching to and from, 185-186  
 time course of action, 166t, 168  
 vs NPH, 184-185
- Dextrose  
 treatment of diabetic ketoacidosis with, 286  
 treatment of HHNS with, 289-290
- DiaBeta (glyburide). See *Glyburide*.
- Diabetes Exercise and Sports Association (DESA), 352
- Diabetes mellitus, 13-20  
 cardiovascular disease risk and, 40-44  
 cause-of-death statistics, 17, 297  
 characteristics of, 29-36, 30t-31t  
 classification of, 29-36, 30t-31t  
 diagnosis of, 37-46, 38t  
 heterogeneous pathophysiology of, 23-24  
 incidence of, 16-19, 16, 17, 18  
 insulin-dependent. See *Type 1 diabetes mellitus*.  
 non-insulin-dependent. See *Type 2 diabetes mellitus*.  
 prevalence of, 13-16, 14, 15  
 resources and publications on, 351-357  
 secondary to other conditions, 30t-31t  
 subclasses of, 29, 30t-31t  
 symptoms of, 37
- Diabetes Prevention Program (DPP), 338t, 339-340
- Diabetes prevention trials. See *Primary prevention trials, diabetes*.
- Diabetes Warranty Program, 40, 42-43
- Diabetic dyslipidemia. See *Dyslipidemia*.
- Diabetic ketoacidosis (DKA), 279-293  
 compared with HHNS, 287, 288t  
 differential diagnosis, 281-282  
 factors affecting development of, 279-281

- Diabetic ketoacidosis (DKA) (*continued*)  
 laboratory evaluation, 282, 283t  
 pathophysiology, 281  
 precipitating factors, 280-281  
 signs and symptoms, 281-282, 282t  
 treatment, 246, 282-286  
   bicarbonate therapy, 284, 286  
   colesevelam not recommended for, 152  
   fluid and electrolyte replacement, 284  
   insulin therapy, 284, 285  
   length of, 286  
   phosphate replacement, 284, 286  
   potassium replacement, 284, 285-286  
   saxagliptin not recommended for, 125
- Diabetic nephropathy, 317-321  
 definition of, 317  
 evaluation/screening for, 318-319  
 factors contributing to, 317-318  
 glycemic control and, 319-320  
 microalbuminuria in, 317  
 nephrotoxic drugs and, 318  
 treatment, 319-321  
   antihypertensive therapy in, 303, 318, 319, 320  
   improving glycemic control, 319-320  
   protein restriction, 320-321
- Diabetic neuropathy, 321-330, 321t  
 categories of, 321-330, 321t  
   autonomic, 321t, 324-330  
   diabetic amyotrophy, 321t, 324  
   diabetic diarrhea, 321t, 325  
   gastroparesis, 321t, 324-325  
   impaired cardiovascular reflexes, 321t, 326  
   mononeuropathy, 321t, 324  
   neurogenic bladder, 321t, 326  
   sensorimotor peripheral, 321-324, 321t  
   sexual dysfunction, 321t, 326-330  
   symmetric distal neuropathy, 321t, 322-323, 323  
 painful neuropathies, 322-323, 323  
 prevalence of, 321  
 treatment, 321-330, 323  
   of painful neuropathies, 322-323, 323
- Diabetic retinopathy, 313-317  
 categories of, 313-315  
   nonproliferative, 313-314, 314  
   preproliferative, 314, 315  
   proliferative, 315  
 early diagnosis, value of, 16  
 evaluation and referral, 315-316, 316t  
 glycemic control and, 313  
 patient education about, 313  
 referral, reasons for, 316t  
 treatment, 316-317
- Diabinese. See *Chlorpropamide*.
- Diagnosis of diabetes, 37-46, 38t  
 asymptomatic presentation, 37  
 cardiovascular risk assessment and, 40-44  
 criteria for, 33t, 38t, 246  
   fasting blood glucose, 13, 38t  
   plasma glucose concentration, 38t  
 early, importance of, 17, 25-26, 33, 64, 72, 345  
 glucose testing in, 38-40, 38t  
 medical evaluation, 40, 42-43  
 problems with, 35-36
- Diagnosis of impaired fasting glucose (IFG), 25, 33t, 34
- Diagnosis of metabolic/dysmetabolic syndrome, 44-45, 44t, 45t
- Diarrhea, diabetic, 321t, 325
- Didget blood glucose meter, 259t
- Diet, 47-58. See also *Nutrition; Obesity; Weight*.  
 body weight considerations, 49-50, 50t  
 caloric intake, 49, 51, 59, 305, 308t  
 clinical trials involving, 337-340, 338t  
 dietary recommendations, 51-57, 52t  
   alcohol, 52t, 57  
   carbohydrates, 52t, 54-55, 308t  
   fat substitutes, 56  
   fats, 52t, 53-54, 305, 308t  
   fiber, 54, 305  
   fructose, 55  
   protein, 53  
   salt, 52t  
   sucrose (sugar), 52t, 55  
   supplements, 52t, 56-57  
   sweeteners, 55-56  
 for dyslipidemia, 54, 305-308, 308t  
 exercise combined with, 44, 49, 52t, 63-64  
 low-salt, for hypertension, 299  
 self-monitoring of blood glucose recommendations with, 265-268  
 USDA *Dietary Guidelines for Americans*, 49-50, 50
- Dietician, 48
- Digoxin, 82
- Dipeptidyl peptidase-IV inhibitors. See *DPP-IV inhibitors*.
- Diphenoxylate (Lomotil), 325
- Diuretics, 300t, 301t, 304, 320  
 potassium supplementation and, 56  
 secondary diabetes and, 30t
- Division of Diabetes Translation, 353
- Domperidone, 325
- Dopamine receptor agonist, 76t, 152-154. See also *Bromocriptine mesylate*.
- Doxycycline hyclate, 325
- DPP (Diabetes Prevention Program), 338t, 339-340
- DPP-IV  
 degradation of GLP-1, 102, 194  
 resistance to degradation by, 194

DPP-IV inhibitors (linagliptin; saxagliptin; sitagliptin), 76t, 102-135.

See also *Linagliptin; Saxagliptin; Sitagliptin*.

advantages of, 102, 135

in algorithm for treatment, 246

combination agents with metformin

Janumet (sitagliptin/metformin), 77t, 114-115

Kombiglyze XR (saxagliptin/metformin XR), 77t, 126

combination therapy. See *Linagliptin; Saxagliptin; Sitagliptin*.

dosage, 76t-77t, 114-115

one-dose (linagliptin), 127, 134

efficacy and safety trials, 103-113, 115-121, 127-134

FDA approval of, 102

indications for, 102, 114, 126

renal disease patients, use in, 112-113

summary of, 135

DREAM (Diabetes Reduction Assessment With Ramipril and

Rosiglitazone Medication) trial, 338t, 342

Duetact (pioglitazone/glimepiride), 78t, 87-90

dosage, 78t, 98

glycemic control with, 87-90, 91t, 92t

prescribing considerations, 98

Dymelor (acetohexamide), 77t, 138

Dyslipidemia, 54, 304-312. See also *Cholesterol levels; Lipid levels;*

*and specific classes of lipids.*

cardiovascular risk and, 40-44, 304-305

characteristic abnormalities, 304-305

diabetes secondary to, 30t

dysmetabolic syndrome X and, 45t

fructose limitation advised for, 55

IFG and IGT as risk factors for, 25

lipid levels, 306t

lipid-lowering drugs, 308-312, 309t, 310t

treatment decisions based on, 307t

metabolic syndrome risk and, 40, 45t

reduction with T2D treatment, 66

screening for, 305, 306t

treatment recommendations, 41-44, 305-312, 307t

ADA order of priorities for, 308, 309t

clinical trials on pharmacologic agents, 310t

dietary therapy, 54, 305-308, 308t

NCEP stepped approach, 305-308

pharmacologic therapy, 308-312, 309t, 310t

Dysmetabolic syndrome X, 44-45, 45t

Dyspepsia, 151

Dyspnea, in diabetic ketoacidosis, 281, 282t

Ear infections, 295t

Early detection and management. See also *Prevention of diabetes.*

complications, reduction in, 25-26, 33, 297-298

disease progression, prevention/slowing of, 26, 73, 84, 245, 313, 337, 345-347

Early detection and management (*continued*)

mortality, reduction in, 17, 84, 312-313

nonpharmacologic therapy, effectiveness of, 64

Early Treatment Diabetic Retinopathy Study, 316-317

EASD. See *European Association for the Study of Diabetes.*

EasyGluco blood glucose meter, 259t

EasyMax blood glucose meters, 259t

Eclipse blood glucose meter, 259t

Edema

macular, 316

thiazolidinediones and, 99-100, 100t

Education. See *Patient education.*

Elderly patients

acarbose in, 136

cautions in, 168-170

glipizide in, 141

HHNS in, 286

hypoglycemia susceptibility of, 255

insulin-pump therapy and, 180-181

late-onset type 1 diabetes (LADA) in, 181

nateglinide in, 147-148

SFUs in, 140, 141

Electrocardiogram (ECG), in diabetic ketoacidosis, 285

Electrolytes, in diabetic ketoacidosis, 280, 284

Element blood glucose meter, 259t

Endocrinopathies, diabetes secondary to, 30t

Environmental factors in type 2 diabetes, 22, 24-25

Envision blood glucose meter, 259t

Erectile dysfunction. See *Sexual dysfunction.*

Erythromycin, 325, 329

ESRD (end stage renal disease). See *Renal disease.*

Ethnicity

prevalence of diabetes and, 13, 15, 16, 32

risk for diabetes and, 23, 34, 37

screening for diabetes and, 345

Etiology of type 2 diabetes, 21-23

European Association for the Study of Diabetes (EASD), 75, 245

Evolution blood glucose meter, 259t

Exenatide (Byetta), 194-206

in algorithm for treatment, 246

β-cell function with, 195-196, 199-200

body weight effects of, 197t, 198-199, 201-205, 201, 203, 205

combination therapy, 195

with metformin, 81, 195, 196-204, 197t, 200-201, 204, 246

with SFUs, 195, 196-198, 197t, 201, 203, 204

with TDZs, 195, 198, 200-201

contraindications, 206

dosage and administration, 206, 207t

glycemic control with, 196-205

half-life, 195

hypoglycemia and, 196-198, 199

- Exenatide (Byetta) (*continued*)  
 indications for, 195  
 side effects, 199  
 trials and studies of, 195-205  
   comparative and long-term open-label trials, 198-205  
     82-week studies, 200-204, 203, 205  
     exenatide vs insulin glargine, 198-200, 202  
     2-year data, 204-205  
 HEELA, 199  
 phase 2 clinical trials, 195-196  
 phase 3 clinical trials, 196-198, 197t, 200-201  
 vs insulin glargine, 198-200, 202  
 vs liraglutide, 221, 222
- Exendin-4, 194-195
- Exercise, 59-62  
 benefits of, 52t, 59  
 combined with diet, 44, 49, 51, 63-64  
   clinical trials involving, 337-340, 338t  
   as first line therapy, 44  
 guidelines/prescription, 60, 61t  
 heart rate in, 61t  
 hypoglycemia induced by, 59-60, 293  
 macrovascular disease risk reduction with, 299  
 precautions and considerations, 59-60, 61t  
 safety in, 59-60, 61t  
 self-monitoring of blood glucose recommendation with, 60  
 in treatment of hypertension, 299  
 in treatment of metabolic syndrome, 44  
 in weight loss program, 44, 51, 59, 60
- Eyes. See also *Diabetic retinopathy*.  
 blurred vision, 37, 291, 296, 316t  
 diabetic ketoacidosis and, 282t  
 routine testing/exams in diabetes, 249, 316
- Family history  
 as risk factor for CHD, 41  
 as risk factor for diabetes, 21, 32, 37, 339
- Farsenoid X receptors, 148
- Fasting hyperglycemia, 21-22
- Fasting plasma glucose. See also *Glycemic control; specific agents*.  
 as diagnostic criterion, 13, 25, 37t, 39, 246  
 impaired. See *Impaired fasting glucose (IFG)*.  
 in metabolic syndrome, 44t  
 as predictive of glycemic control, 171  
 target/goal levels, 13, 66t, 298  
 testing for, 25, 39
- Fat  
 body fat distribution, 32, 34. See also *Obesity; Weight*.  
   pioglitazone and, 90  
   rosiglitazone and, 342  
 dietary. See also *Diet; Dyslipidemia; Nutrition*.  
   benefits of restriction of, 53-54, 305  
   Fat, dietary (*continued*)  
     incidence of diabetes and, 16, 22  
     recommendations for, 52t, 53-54, 308  
     restriction for dyslipidemia, 305, 308, 308t  
     substitutes, 56  
 Fatigue, 153, 279  
   diabetic ketoacidosis and, 281  
   hypoglycemia and, 291
- Fatty liver (steatohepatitis), 98
- FDPS (The Finnish Diabetes Prevention Study), 338t, 339
- Fenofibrate (Tricor), 309t, 310t, 311-312
- Fetal hemoglobin, glycemic testing results and, 252
- Fiber, dietary, 54, 305
- Fibrates, 309t, 310t, 312  
   diabetic neuropathy and, 321  
   in Steno-2 Trial, 69
- Fibric acid derivatives, 309t, 310t, 312
- Fifty50 Control Blood Glucose Monitoring System, 260t
- Fingerstick devices, advances in, 272-273
- Finnish Diabetes Prevention Study (FDPS), 338t, 339
- Flatulence, 136
- Fludrocortisone, 326
- Fluid replacement, in diabetic ketoacidosis, 284
- Fluvastatin, 309
- Folic acid supplements, 52t, 69
- Foot disorders in diabetes, 324, 330-331  
   foot exam, 249, 330  
   guidelines for foot care, 330-331, 332t
- Fora blood glucose meters, 260t
- Fortamet, 76t, 83. See also *Metformin (MET)*.
- FGP. See *Fasting plasma glucose*.
- FreeStyle blood glucose meters, 260t
- FreeStyle Navigator blood glucose system, 274
- Fructosamine measurement, 252-253, 253
- Fructose, 55
- Furunculosis, 294t
- Gabapentin (Neurontin), 322, 323
- GAD. See *Glutamic acid decarboxylase*.
- Gastric emptying, 192, 232-233  
   amylin/pramlintide effect on, 230, 232-233, 232  
   delayed, in gastroparesis, 324  
   GLP-1 and, 192, 233  
   postprandial glucose levels and, 65, 232-233
- Gastric inhibitory peptide (GIP), 229
- Gastroenteritis, 282
- Gastrointestinal symptoms  
   bile acid sequestrants and, 151, 311  
   bromocriptine mesylate and, 154  
   diabetic ketoacidosis and, 280, 281, 282t  
   exenatide and, 199  
   in HHNS, 287

- Gastrointestinal symptoms (*continued*)  
 liraglutide and, 221-222  
 metformin and, 81  
 miglitol and, 138  
 pramlintide and, 238-239, 240  
 SFUs and, 139  
 sitagliptin and, 106
- Gastroparesis, 321t, 324-325
- GDM. See *Gestational diabetes mellitus (GDM)*.
- gDrive blood glucose meter, 261t
- Gemfibrozil (Lopid), 309t, 310t, 311-312
- Gender, prevalence of diabetes and, 13, 37
- Genetic syndromes, diabetes secondary to, 30t
- Genetics  
 component in cardiovascular disease, 40  
 component in type 2 diabetes, 16, 21, 32, 37  
 thrifty gene hypothesis, 16
- Gestational diabetes mellitus (GDM), 30t, 34-35  
 diagnosis, 39-40  
 as risk factor for type 2 diabetes, 35, 37  
 screening for, 35, 39-40
- Gila monster, 194, 195
- GIP (gastric inhibitory peptide), 229
- GIP (glucose-dependent insulinotropic polypeptide), 102, 191, 192
- Glargine (Lantus), 162, 185-187. See also *Insulin therapy*.  
 combination therapy, 183, 218t-219t  
 dosage, 187  
 hypoglycemia with, 177, 177  
 ORIGIN trial, 344  
 regimens for, 179  
 switching to and from, 180, 185-186  
 time course of action, 166t, 168  
 Treat-to-Target Study, 176-177, 176, 185  
 vs exenatide, 198-200, 202
- Glibenclamide, 131
- Glicazide  
 in combination with linagliptin, 131  
 in Steno-2 Trial, 69
- Glimepiride (Amaryl), 77t, 141. See also *Sulfonylureas*.  
 combination formulations  
 with pioglitazone (Duetact), 78t, 87-90, 91t, 92t, 98  
 with rosiglitazone (Avandaryl), 78t, 84  
 combination therapy  
 with insulin, 141  
 with linagliptin, 131  
 with liraglutide, 209-215, 210t-213t, 218t-219t  
 with sitagliptin, 111  
 dosage, 77t, 141  
 for Avandaryl, 78t  
 for Duetact, 78t, 98
- Glimepiride (Amaryl) (*continued*)  
 lack of weight gain with, 141  
 vs liraglutide, 208-209, 210t
- Glinides, 77t, 142-148. See also *Nateglinide; Repaglinide*.  
 action mechanisms, 142, 145-146  
 in algorithm for treatment, 246  
 combination therapy  
 with biguanide (metformin), 77t, 81, 142-143  
 with TZDs, 142  
 dosing/prescription considerations, 77t, 142, 144-147  
 efficacy, 142-146  
 glycemic control with, 143, 143  
 hypoglycemia and, 144, 147  
 side effects, 144, 147-148
- Glipizide (Glucotrol), 77t, 141. See also *Sulfonylureas*.  
 combination therapy  
 with metformin (Metaglip), 78t, 83  
 with sitagliptin, 110-111  
 dosing, 77t, 141  
 once-a-day, 141  
 extended release (Glucotrol XL), 77t, 139, 141  
 safety and benefits of, 141
- Glipizide/metformin (Metaglip), 78t, 83. See also *Glipizide; Metformin*.
- Glitazones, 312
- GLP-1 (glucagonlike peptide 1), 102, 191-194, 192.  
 See also *DPP-IV inhibitors; GLP-1 analogues*.  
 agonists for, 191-228  
 body weight effects, 193, 224  
 degradation by DPP-IV, 102  
 DPP-IV inhibitors and, 102  
 functions of, 191-194  
 gastric emptying and, 192, 233  
 glucoregulatory effects of, 191-194  
 half-life, 194  
 production of, 191, 192  
 receptors, 191
- GLP-1 analogues, 194-224. See also *Exenatide; Liraglutide*.  
 combination therapy with metformin, 81  
 dosing and administration, 206, 207t, 223-224  
 efficacy and safety trials, 195-221  
 indications for, 195, 206  
 specific agents  
 exenatide (Byetta), 194-206  
 liraglutide (Victoza), 206-224  
 summary of, 224
- GLP agonists, 191-228. See also *GLP-1 analogues*.  
 multihormonal control of glucose and, 192  
 production of, 191  
 rationale for use, 191-194

- Glucagon, 64-65, 192, 229, 233. See also *GLP-1 (glucagonlike peptide 1)*; *GLP-1 analogues*.  
 intramuscular, for severe hypoglycemia, 292  
 proglucagon, 191  
 suppression of hypersecretion, 64-65, 233  
 with amylin/pramlintide, 231, 232, 233  
 with GLP-1, 191, 193
- Glucagonlike peptide. See *GLP-1*.
- Glucagonoma, diabetes secondary to, 30t
- Glucocard blood glucose meters, 261t
- Glucolab blood glucose meter, 261t
- Glucophage (metformin), 76t. See also *Metformin (MET)*.  
 in Diabetes Prevention Program (DPP), 338t, 339-340
- Glucophage XR, 76t, 83. See also *Metformin (MET)*.
- Glucoregulatory hormones. See also *specific hormones*.  
 amylin, 229-232  
 incretin hormones, 102, 191-194, 192  
 insulin. See *Insulin*.  
 multihormonal control of glucose homeostasis, 192
- Glucose, as treatment for severe hypoglycemia, 292
- Glucose-dependent insulinotropic polypeptide (GIP), 102, 191, 192
- Glucose homeostasis, 230-232, 232. See also *Pramlintide therapy*.  
 multihormonal control of, 192, 229
- Glucose intolerance, disorders of, 30t-31t
- Glucose levels, 38-40, 38t. See also *Glycemic control*; *Plasma glucose concentration (PGC)*; *Postprandial glucose (PPG)*.  
 in diabetic ketoacidosis, 283t, 285, 288t  
 as goal of nutrition therapy, 49  
 in HHNS, 288t, 289  
 intensive control of, CV risk and, 67-72  
 measuring, 249-251  
 monitoring. See *Glucose monitoring*.  
 multihormonal control of, 192, 229  
 normal, 38t, 244t  
 targets/goals for, 13, 244t, 298
- Glucose monitoring, 249-278  
 advances in, 272-277  
 bloodletting devices, 272-273  
 computer-assisted data analysis, 258t-264t, 272  
 continuous glucose monitoring, 273-277  
 noninvasive monitoring, 277  
 glycated hemoglobin, measuring, 251-252  
 interstitial glucose measurements, 277  
 plasma glucose levels, measuring, 249-251  
 self-monitoring, 253-277, 258t-264t. See also *Self-monitoring of blood glucose (SMBG)*.  
 blood glucose meters, 258t-264t, 272  
 contact information for manufacturers, 266t-267t  
 continuous glucose monitoring systems, 273-277  
 recommendation for all diabetes patients, 257  
 recommended frequency of, 265  
 timing of, 250-251
- Glucose production, hepatic  
 amylin/pramlintide action on, 230, 232  
 insulin and amylin actions on, 230, 232  
 in pathogenesis of type 2 diabetes, 21-22, 22, 64  
 in transition from IGT to type 2 diabetes, 22, 24, 25, 25  
 weight loss and, 49
- Glucose sensitivity, weight loss and, 49
- Glucose testing, 38-40, 38t. See also *Glucose monitoring*.  
 oral glucose tolerance test (OGTT), 25, 38t, 39
- Glucose tolerance, impaired. See *Impaired glucose tolerance*.
- Glucose toxicity, 23, 63  
 diabetic ketoacidosis and, 280  
 insulin therapy for, 80, 162
- Glucotrol, Glucotrol XL. See *Glipizide*.
- Glucovance (glyburide/metformin), 78t, 82-83. See also *Glyburide*; *Metformin*.
- Glulisine (Apidra), 162, 182  
 time course of action, 162, 164-165, 166t
- Glumetza, 76t, 83. See also *Metformin (MET)*.
- Glutamic acid decarboxylase (GAD) antibodies, 36, 161, 181
- Glyburide (DiaBeta, Micronase, Glynase PresTab), 77t, 141.  
 See also *Sulfonylureas*.  
 cautions for, 141  
 combination formulation with metformin (Glucovance), 78t, 82-83  
 combination therapy, with saxagliptin, 119, 122t-123t  
 dosing considerations, 77t, 141  
 Glynase PresTab (micronized formulation), 77t, 139, 141  
 hypoglycemia and, 141
- Glyburide/metformin (Glucovance), 78t, 82-83
- Glycated hemoglobin assay/measurement, 251-252. See also *Glucose monitoring*; *Glycosylated hemoglobin (A1C)*.
- Glycated proteins, measurement of, 252-253, 253
- Glycation, defined, 251
- Glycemic control. See also *Glucose homeostasis*; *Glucose monitoring*;  
*specific treatments and agents*.  
 in algorithm for treatment, 245, 246-247  
 benefits of, 66-67, 67t, 73, 298, 313, 319  
 diabetic nephropathy and, 319-320  
 FBG level as predictor of, 171  
 intensive therapy for, 65-72, 298  
 monitoring, 249-278  
 targets/goals for, 65, 66t, 69-70, 72, 250t, 298  
 summary of, 244t, 245  
 weight loss and, 49
- Glycosylated hemoglobin (A1C). See also *specific treatments and agents*.  
 measurement of, 251-252  
 correlation with diabetic control, 251  
 disposable test kit (Metrika), 252  
 false lows and highs, 251-252  
 home measurement kits, 252  
 lack of standardization in, 39

Glycosylated hemoglobin (A1C) (*continued*)  
 monitoring, 249-278  
 normal value, 244t  
 postprandial hyperglycemia and, 65  
 targets/goals for, 66t, 71, 72, 244t, 245, 250t, 298  
 trials and studies  
   in Steno-2 Trial, 69  
   UKPDS, 66, 68-69, 68  
   VADT, 70

Glynase PresTab (glyburide), 77t, 139, 141. See also *Glyburide*.

Glyset. See *Miglitol*.

Guardian Real-Time blood glucose system, 274

Gut hormones. See *Incretin hormones*.

Hagedorn (neutral protamine Hagedorn). See *NPH*.

HDL. See *High-density lipoprotein (HDL)*.

Headache, 113, 125, 153, 154

Healing, abnormal, 37

Heart failure, 99-100, 100t

Heart of Diabetes, The (American Heart Association), 353

Heart Outcomes Prevention Evaluation trial (HOPE), 302, 346t

HEELA (Helping Evaluate Exenatide in Overweight Patients With Diabetes Compared With Long-Acting Insulin) study, 199

*Heloderma suspectum* (Gila monster), 194

Helsinki trial, 310t

Hematologic reactions, 140

Hemochromatosis, 30t, 327

Hemolytic anemia, 251

Hepatic glucose production. See *Glucose production, hepatic*.

Herbal supplements, 57

HHNS. See *Hyperosmolar hyperglycemic nonketotic syndrome*.

High-density lipoprotein (HDL), 37, 304  
 cholesterol  
   CV risk and, 41-43, 304-305  
   levels, 306t  
   low, treating, 312  
   in metabolic syndrome, 44t  
   raising, 309t, 312  
   saturated fat intake and, 54  
   target/goal level, 250t, 306t  
 in metabolic/dysmetabolic syndrome, 44t, 45t  
 pioglitazone and, 90, 95

Hispanic/Latino Americans. See also *Race/ethnicity*.  
 incidence of diabetes in, 16  
 prevalence of diabetes in, 13, 15, 32  
 risk of diabetes in, 37

HMG-CoA reductase inhibitors, 45, 148, 309-311, 309t, 310t  
 combination therapy with colestevlam, 148, 311  
 contraindications/cautions, 311-312

HOMA-B, 108, 195-196

Home monitoring. See *Self-monitoring of blood glucose*.

Homeostasis, glucose. See *Glucose homeostasis*.

Homeostasis model assessment (HOMA), 108, 195-196

HOPE (Heart Outcomes Prevention Evaluation trial), 302, 346t

Hormones. See *Glucoregulatory hormones*.

HPS (simvastatin) trial, 310t

Humalog (lispro), 162, 181  
 for diabetic ketoacidosis, 285  
 time course of action, 164-165, 166t, 168

Humalog Mix  
 Humalog Mix 50/50, 162, 182  
 Humalog Mix 75/25, 162, 178, 182  
 time course of action, 167t

Human insulin, 162, 163, 229. See also *Insulin therapy*.

Humulin 70/30, 50/50, 167t

Huntington's chorea, diabetes secondary to, 30t

Hypercoagulability, dysmetabolic syndrome X and, 45t

Hyperglycemia, 22, 63, 64-65  
 classic symptoms of, 246  
 diabetic ketoacidosis and, 280, 281, 282t  
 diabetic nephropathy and, 317, 319, 320  
 diabetic retinopathy and, 313  
 in diagnosis of diabetes, 29, 246  
 fasting, 21-22, 64  
 postprandial, 64-65  
   as common denominator in diabetes syndromes, 29  
   importance of controlling, 64-65  
   target PPG levels, 66t  
 premeal, techniques to adjust for, 268t  
 prolonged, 63  
 severe, SMBG in preventing, 255

Hyperinsulinemia, 22, 140, 187

Hyperosmolar hyperglycemic nonketotic syndrome (HHNS), 286-290  
 diagnosis, 289  
 laboratory evaluation, 288t, 289  
 pathophysiology, 287  
 symptoms and signs of, 287-289, 288t  
 treatment of, 289-290  
 vs diabetic ketoacidosis, 287, 288t

Hyperprolactinemia, 327

Hypertension, 299-304  
 antihypertensive drugs, 299-304, 300t, 345  
   benefits of, 301t  
   clinical trials involving, 346t  
   complications of, 300t  
   diabetes risk reduction with, 345, 346t  
   secondary diabetes and, 30t  
   side effects of, 299, 300t  
   blood pressure goals, 299  
 in criteria for dysmetabolic syndrome X, 45t  
 diabetic nephropathy and, 317-318, 319  
 IFG and IGT as risk factors for, 25

Hypertension (*continued*)

as risk factor  
for CHD, 41  
for diabetes, 37, 345  
for metabolic syndrome, 41, 45t  
treatment of, 44-45, 299-304, 300t, 320  
in treatment of metabolic syndrome, 44-45  
Hypertriglyceridemia, 304, 312. See also *Dyslipidemia*.  
Hyperuricemia, dysmetabolic syndrome X and, 45t  
Hyperventilation, diabetic ketoacidosis and, 281, 282, 282t  
Hypoglycemia, 279, 290-293  
causes of, 290  
diabetic ketoacidosis and, 282  
education about, 170, 293  
emergency kits for, 292  
exercise and, 59-60  
factors contributing to, 290  
glucagon for, 292  
glucose for, 292  
moderate vs severe, 291, 292  
nocturnal, 177, 177t, 291, 293  
prevention of, 170, 255, 293  
safety of acarbose, 135  
severe, 291, 292  
β-blockers and, 303  
pramlintide and, 239  
as side effect  
of bromocriptine mesylate, 154  
of chlorpropamide, 139  
of colesevelam, 151  
of exenatide, 196-198  
of glinides, 144, 147  
of insulin therapy, 170, 188, 229, 290  
of linagliptin, 128, 129, 133  
of liraglutide, 223  
of pramlintide, 239  
of saxagliptin, 125  
of SFUs, 139-140  
of sitagliptin, 106, 112, 113  
signs of, 290-291  
SMBG and, 188, 255, 293  
treatment of, 291-293  
Hyponatremia, with sulfonyleureas, 139  
Hyporeflexia, in diabetic ketoacidosis, 282t  
Hypotension, orthostatic, 326  
antihypertensive drugs and, 300t, 303  
Hypothermia, in diabetic ketoacidosis, 282t  
Hypotonia, in diabetic ketoacidosis, 282t

ICD-9 code (for metabolic/dysmetabolic syndrome), 45  
IDF (International Diabetes Federation), 354-355  
IFG. See *Impaired fasting glucose*.  
IGT. See *Impaired glucose tolerance*.  
Imodium (loperamide), 325  
Impaired fasting glucose (IFG), 34, 337  
diagnostic criteria for, 25, 33t, 34  
in DREAM trial, 342  
in metabolic/dysmetabolic syndrome, 44t, 45t  
in ORIGIN trial, 344  
as risk factor, 14, 25, 37  
Impaired glucose tolerance (IGT)  
as cardiovascular risk factor for, 41  
characteristics of, 25, 30t-31t, 33-34  
diagnosis, 33-34, 33t  
glucose production in, 21-22  
insulin secretion and, 23  
macrovascular disease and, 34  
metabolic syndrome and, 41  
oral glucose tolerance test and, 25  
as risk factor, 25, 37, 337  
screening for, 25  
transition to type 2 diabetes, 22-23, 24, 34  
factors influencing, 34  
trials and studies  
ACT-NOW trial, 343-344, 343  
Da Qing IGT and Diabetes Study, 337-339, 338t  
DREAM trial, 338t, 342  
FDPS (Finnish Diabetes Prevention Study), 338t, 339  
ORIGIN trial, 344  
STOP-NIDDM, 338t, 341  
Impotence. See *Sexual dysfunction*.  
Incidence of diabetes, 16, 32  
by age, 16, 18, 19  
definition of, 16  
factors affecting, 16  
increase in, 13, 16, 17, 19  
Incretin effect, 102, 191  
Incretin hormones, 102, 191-194, 192. See also *DPP-IV inhibitors*;  
*GLP-1 analogues*.  
DPP-IV inhibitors and, 102-135  
effects of, 102, 191-194  
GLP-1 analogues and, 194-224  
rationale for use, 191-194  
summary of uses and effects, 224  
Incretin mimetics. See *GLP-1 analogues*.  
Indapamide, 320  
Indian Health Services (IHS), 353-354  
Indians, American. See *American Indians*.  
Indinavir, 125

- Infection, 293, 294t-295t  
 common infections in diabetes patients, 294t-295t  
 diabetic ketoacidosis and, 280  
 as symptom of diabetes, 37
- Infinity blood glucose meter, 261t
- Insulin. See also *Insulin therapy*.  
 action mechanism, 162, 192, 230  
 normal time course of, 168  
 allergy to, 163  
 antibodies to, 29, 163, 170  
 cosecretion with amylin, 230, 231  
 deficiency, 24, 161, 279  
 β-cell exhaustion and, 161, 230  
 in diabetic ketoacidosis, 279  
 GLP-1 and, 191-192, 193  
 multihormonal control of, 192  
 to treat hyperglycemia, 80  
 types of preparations, 162-163, 166t-167t  
 human, 162, 163  
 insulin analogues, 162-165  
 new types of, 181-187  
 premixed, 162-163  
 recombinant DNA, 184, 185  
 selecting, 162-168
- Insulin-dependent diabetes. See *Type 1 diabetes mellitus*.
- Insulin receptor abnormalities, 30t
- Insulin resistance, 21-23, 32, 63, 180. See also *Metabolic syndrome*.  
 cardiovascular disease and, 40  
 compensated, 22-23  
 early damage from, 14-16, 83  
 factors influencing, 22, 40-41  
 metabolic/dysmetabolic syndrome and, 45t  
 present prior to diabetes diagnosis, 24  
 reduction with TZDs, 83-84, 101  
 severe, insulin antibodies and, 163  
 in transition from IGT to type 2 diabetes, 22-23, 24
- Insulin secretion  
 impaired, 22, 23, 24, 64  
 in prediabetic or IGT state, 22
- Insulin therapy, 161-190. See also *specific formulations/preparations of insulin*.  
 action mechanism, 162  
 algorithm for, 170, 171, 246  
 basal, 163  
 benefits of, 162  
 bolus, 163, 179  
 cautions for, 168-170  
 combination therapy, 170-177, 246  
 with acarbose, 136  
 in algorithm for treatment, 246-247  
 benefits of, 172-173
- Insulin therapy, combination therapy (*continued*)  
 dosing guidelines/calculation, 173, 173t  
 adding predinner premixed insulin to daytime oral medications, 175t  
 maximum dose of oral agent, 175  
 with glimepiride, 148  
 glycemic control with, 175-176, 176  
 most common clinical situation for, 175-176  
 patient selection for, 171-172  
 patient self-adjustment with SMBG, 174, 174t  
 with pramlintide, 229-230, 234, 235, 236, 237  
 rationale for, 170-171, 175  
 with rosiglitazone, 84  
 with SFUs, 141  
 with sitagliptin, 103, 112  
 timing of doses, 173-174, 173t  
 Treat-to-Target Studies, 176-177, 176
- complications of, 187-188  
 hypoglycemia, 188  
 weight gain, 187-188  
 for diabetic ketoacidosis, 284, 285  
 dosage, self-adjustment via SMBG data, 174, 174t, 269-272, 274t  
 eating close to injection time, 165  
 for HHNS, 289  
 hypoglycemia and, 177, 177, 188, 229, 290  
 education about, 170  
 indications for, 161-162  
 individual tailoring of, 170  
 initiation of, 161, 178-179, 180  
 insulin preparations, 162-165  
 fast-acting analogues, 162, 163, 164-165  
 aspart (Novolog), 162, 164-165, 168, 182  
 glulisine (Apidra), 162, 164-165, 168, 182  
 lispro (Humalog), 162, 164-165, 168, 181  
 time course of action, 162, 164-165, 166t, 168  
 human insulin, 162, 163  
 insulin analogues, 162-165  
 intermediate-acting (NPH), 163, 166t  
 long-acting analogues, 162  
 detemir (Levemir), 162, 184-185  
 glargine (Lantus), 162  
 time course of action, 166t  
 newer preparations, 181-187  
 aspart (Novolog), 182  
 detemir (Levemir), 184-185  
 glargine (Lantus), 185-187  
 glulisine (Apidra), 182  
 lispro (Humalog), 181  
 recombinant DNA-produced, 184, 185  
 premixed, 162-163, 182-184  
 advantages of, 183  
 disadvantage of, 183-184

Insulin therapy, insulin preparations, premixed (*continued*)

Humalog Mix 50/50 (lispro), 182  
Humalog Mix 75/25 (lispro), 182  
Novolin 70/30 (NPH-insulin), 183  
Novolog Mix 70/30 (aspart), 182, 183  
time course of action, 167t, 182-183  
regular insulin, 163, 168  
selection guidelines, 163-168  
short-acting (regular insulin), 163  
time course of action, 166t, 168  
short/fast-acting, 163  
time course of action, 162, 164-165, 166t, 168  
intensive, 168-170  
algorithm form for, 274-275  
patient selection for, 168  
intermittent, 163  
ORIGIN trial, 344  
pump therapy, 169t, 180-181, 246  
switching regimens to or from, 186  
rationale for, 170-171  
regimens for, 169t  
basal bolus strategy, 179-180  
combined with oral agents, 169t  
continuous subcutaneous insulin infusion (CSII), 246  
multiple-injection, 169t, 177-180, 246  
multiple-daily-injection (MDI), 179, 180  
natural progression in, 161, 170, 180  
pump therapy, 169t, 180-181  
single-injection, 169t  
site of injection and, 164, 170  
split-mixed, 177, 178-179, 246, 276t  
switching to and from, 185-186  
selection of insulin preparation, 162-168  
common regimens, 169t  
factors affecting, 164-165  
time course of action and, 164, 168  
self-monitoring of blood glucose (SMBG), 269-272  
dosage adjustment and, 174, 174t  
record sheet, 269, 270-271  
time course of action, 163-165, 164-165, 166t-167t, 168  
timing of, 52t, 241  
Intensive therapy for Type 2 diabetes, 65-72  
intensive glucose control, CV risk and, 67-72  
intensive insulin therapy, 168-170. See also *Insulin therapy*.  
algorithm form for, 274-275  
reduced long-term complications with, 298  
International Diabetes Center at Park Nicollet, 354  
International Diabetes Federation (IDF), 354-355  
Intestinal peptides, 102, 191-194. See also *Incretin hormones*.  
Irbesartan, 320  
Iron, serum, in diabetic impotence, 327

Islet cell antibody (ICA), 29, 161

Isophane. See *NPH*.

Itraconazole, 125

Janumet (sitagliptin/metformin), 77t, 114-115

Januvia. See *Sitagliptin*.

JDRF (Juvenile Diabetes Research Foundation) International, 355

Joslin Diabetes Center, 355

Juvenile Diabetes Research Foundation (JDRF) International, 355

Ketoacidosis. See *Diabetic ketoacidosis*.

Ketoconazole, 125

Ketonemia in type 2 diabetes, 32

Ketones

in diabetic ketoacidosis, 280, 283t, 285, 288t

in HHNS, 288t

serum, measurement of, 253

Ketosis, 280, 286. See also *Diabetic ketoacidosis*.

Kidney disease. See also *Diabetic nephropathy*; *Renal function*.

acarbose safety in, 136

Kidney function. See *Renal function*.

Kombiglyze XR (saxagliptin/metformin XR), 77t, 126

Kussmaul's respiration

in diabetic ketoacidosis, 282t

in HHNS, 287

Lactic acidosis, metformin therapy and, 81-82

LADA (Late-onset type 1 diabetes), 181

LADA (latent autoimmune diabetes in adults), 162

Lantus. See *Glargine*.

Laser photocoagulation, 316-317

Late-onset type 1 diabetes (LADA), 181

Latent autoimmune diabetes in adults (LADA), 162

Latino Americans. See *Hispanic/Latino Americans*.

LDL. See *Low-density lipoprotein (LDL)*.

LEAD (Liraglutide Effect and Action in Diabetes) trials, 208-221,  
210t-213t, 214, 216t-219t, 220

Lean type 2 diabetic patients, 64

Lente, 173, 174t, 185. See also *Ultralente*.

Levemir. See *Detemir*.

Levitra (vardenafil), 327-329, 328t

LIFE study, 346t

Lifestyle modifications, 47-62, 309t. See also *Diet*; *Exercise*; *Nutrition*.

clinical trials involving, 337-340, 338t

concurrent with oral agents, 75, 245

as initial treatment approach, 47, 59, 245, 246

combined with metformin, 75, 245, 246

Lifestyle, sedentary, as risk factor for diabetes, 13, 22, 25, 34, 38, 59

Linagliptin (Tradjenta), 75, 76t, 126-134

adverse events, 129, 134

approval in the United States, 102

- Linagliptin (Tradjenta) (*continued*)  
 β-cell function and, 128  
 body weight and, 129, 133  
 combination therapy, 129-133  
   with metformin, 129, 130, 131, 132t  
   with pioglitazone, 131-133, 133, 134  
   with SFU, 130-131, 132t, 134  
 dosage, 76t, 127, 134  
 no dose adjustment needed, 127, 134  
 glycemic control with, 127-133, 128  
 hypoglycemia and, 128, 129, 133  
 indications for, 126-127  
 pharmacokinetics, 127  
 in renal or hepatic impaired patients, 127, 134  
 tolerability of, 129  
 trials, 127-134  
   combination or add-on treatment, 129-133  
   long-term treatment, 133-134  
   monotherapy trials, 127-129, 128
- Lipid levels, 54, 304-312. See also *Dyslipidemia*; *High-density lipoprotein*; *Low-density lipoprotein*; *Triglycerides*.  
 for adults (low, borderline, high-risk), 306t  
 cardiovascular risk and, 54, 304  
 colesivelam and, 148  
 diet and, 47, 54  
 goals for, 41, 250t  
 linagliptin and, 134  
 lipid-lowering pharmacologic agents, 69, 308-312, 309t, 310t  
 metformin and, 81  
 pioglitazone and, 90-93  
 rosiglitazone and, 90-93  
 treatment decisions based on, 307t
- Lipoproteins. See *High-density lipoprotein (HDL)*; *Low-density lipoprotein (LDL)*.
- Liraglutide (Victoza), 206-224  
 action mechanism, 206  
 adverse events, 221-223  
 in algorithm for treatment, 246  
 amino acid sequence, 206  
 body weight effects of, 208, 209, 213t, 215, 216t, 218t, 220-221  
 combination therapy, 206  
   with glimepiride, 209-215, 210t-213t, 218t-219t  
   with metformin, 206, 215-221, 216t-219t, 220, 246  
   with SFU, 206  
   with TZD, 206  
 contraindications, 223-224  
 dosage and administration, 207t, 223-224  
 FDA approval of, 194  
 glycemic control with, 206-221  
 hypoglycemia and, 223  
 indications for, 206  
 safety and tolerability of, 221-223
- Liraglutide (Victoza) (*continued*)  
 trials and studies of, 206-221  
   phase 2 clinical trials, 206-208  
   phase 3 clinical trials, 208-221  
   in combination with one OAD, 209-215  
   in combination with two OADs, 215-221  
   LEAD, 208-221, 210t-213t, 214, 216t-219t, 220  
   monotherapy (LEAD-3), 208-209, 210t, 212-213t  
   with rosiglitazone, 209-221, 210t-211t, 214, 220  
 vs exenatide, 221, 222  
 vs glimepiride, 208-209, 210t
- Lisinopril, in ALLHAT, 346t
- Lispro (Humalog), 162, 181. See also *Humalog*; *Humalog Mix*.  
 combined with pramlintide, 234, 235  
 time course of action, 164-165, 166t
- Liver function  
 fatty liver (steatohepatitis), 98  
 glipizide and, 141  
 monitoring, 98-99  
 nateglinide and, 148  
 oral agent contraindications/cautions for, 98  
 thiazolidinediones and, 98-99
- Lomotil (diphenoxylate), 325
- Long-term complications. See *Complications of diabetes, long-term*.
- Loop diuretics, 82, 300t, 301t, 304, 320
- Loperamide (Imodium), 325
- Lopid. See *Gemfibrozil*.
- Losartan, 320, 346t
- Lovastatin, 309
- Low-density lipoprotein (LDL)  
 cholesterol  
   calculation of, 305  
   CHD and, 41  
   high-protein diets and, 53  
   metformin and, 81  
   target/goal levels, 41, 250t, 305, 306t, 307t  
   treatment recommendations based on, 305-308, 307t  
   goal levels, 41, 250t  
 lowering, 305-308, 309t  
   with bile acid sequestrants, 309  
   with fibrates, 312  
   with HMG-CoA reductase inhibitors, 45, 309-310, 309t  
   with nicotinic acid, 309t  
 in metabolic syndrome, 45  
 phenotype B pattern, 305  
 pioglitazone and, 90  
 in Steno-2 Trial, 69

MACE (major adverse cardiac events), 95

Macrovascular disease, 298-312

- dyslipidemia and, 304-312
- early damage from, 14-16
- hypertension, 299-304
- IGT and, 34
- major diseases of, 298
- reduction with early diagnosis and treatment, 25-26
- risk factors in, 298

Macrovascular events, pioglitazone and (PROactive Study), 93-97

Macular edema, in diabetic retinopathy, 316, 316t.

- See also *Diabetic retinopathy*.

Malnutrition-related diabetes mellitus, 30t

Maturity-onset diabetes of the young, 35

Maxima blood glucose meter, 261t

Meal plan, 48

Medical evaluation (Diabetes Warranty Program), 40, 42-43

Medical Urethral System for Erection (MUSE), 329

Meglitinide . See *Repaglinide (Prandin)*.

MET. See *Metformin*.

Metabolic abnormalities in T2D, 21-23, 24, 24, 63, 64

- goals for treatment, 63, 65, 66t, 244t, 250t

Metabolic acidosis, 281-282. See also *Diabetic ketoacidosis*.

Metabolic complications of T2D, 279-293. See also *Complications of diabetes*.

Metabolic control. See *Glycemic control*.

Metabolic goals of treatment, 63, 65, 66t, 244t, 250t, 298

Metabolic syndrome, 44-45

- criteria for, 44t, 45t
- risk factors for, 40-41
- therapy for, 44-45

Metaglip (glipizide/metformin), 78t, 83

Metformin (MET), 76t, 80-83

- action mechanism, 80
- in algorithm for treatment, 246
- benefits of, 75, 80, 81
- combination formulations, 77t-78t
  - with glipizide (Metaglip), 78t, 83
  - with glyburide (Glucovance), 78t, 82-83
  - with pioglitazone (Actoplus Met/Actoplus Met XR), 78t, 86-87, 88t-89t, 97-98
  - with repaglinide (Prandimet), 77t, 144-145
  - with rosiglitazone (Avandamet), 78t, 84
  - with saxagliptin (Kombiglyze XR), 77t, 126
  - with sitagliptin (Janumet), 77t, 114-115
- combination therapy, 80-83, 246
  - with acarbose, 136
  - with bromocriptine mesylate, 246
  - with colesevelam, 81, 149, 246
  - with DPP-4 inhibitor, 246
  - with exenatide, 81, 195, 196-204, 200-201, 204, 246
- Metformin (MET), combination therapy (*continued*)
  - with glinides, 81
  - with insulin/insulin preparations, 81, 183
  - with linagliptin, 129, 130, 131, 132t
  - with liraglutide, 206, 215-221, 216t-219t, 220, 246
  - with nateglinide, 142-143, 143, 145, 147
  - with Novolog Mix, 183
  - with pramlintide, 230
  - with repaglinide, 142-143, 143
  - with rosiglitazone, 78t, 84
  - with saxagliptin, 117-119, 118, 120t, 121
  - with SFUs, 78t, 80-81, 246
  - with sitagliptin, 107, 109, 112
  - with TDZs, 78t, 81, 246
  - triple-combination (TZD/repaglinide/MET), 103, 114, 136, 144
- contraindications/cautions, 82
- dosage/titration, 75, 76t, 82
  - in combination therapy, 77t-78t, 82
- effect on lipids, 81
- formulations/trade names, 76t-79t
  - extended-release, 83
- hypoglycemia and, 80
- as initial therapy, 25, 75, 80, 245, 246
- monotherapy, 78
- prescribing considerations, 82
- in prevention of diabetes, 25
- side effects, 81-82, 126
  - lactic acidosis, 81-82
  - minimization of, 81
- trials and studies
  - DPP, 338t, 339-340
  - Steno-2 Trial, 69
  - UKPDS, 67-69
  - vs nateglinide, 146, 147
  - vs pioglitazone, 97
  - weight loss with, 81

Metoclopramide HCl, oral, 325

Metronidazole, 325

Microalbumin, measurement of, 253

Microalbuminuria, 44-45

- Candesartan and Lisinopril Microalbuminuria study, 303
- in diabetic nephropathy, 317, 318-319, 320
- glycemic threshold for developing, 320
- macrovascular disease risk and, 298
- in metabolic/dysmetabolic syndrome, 45, 45t
- in Steno-2 Trial, 69, 70
- treatment of, 44-45

Microaneurisms. See *Diabetic retinopathy*.

Micronase (glyburide). See *Glyburide*.

Micronized particles, in Glynase PresTab, 141

Microvascular complications of diabetes, 297, 312-330

- prevention, as treatment goal, 245, 297-298, 312-313

Microvascular disease, 297, 312-330  
reduction with glycemic control, 26, 66, 67t, 70, 297-298

Migliitol (Glyset), 76t, 138  
action mechanism, 138  
combination therapy with repaglinide, 144  
dosage, 76t, 137t, 138  
PPG levels and, 138  
prescribing considerations, 137t, 138  
side effects, 138

Mineral supplementation, 56-57

MiniMed Paradigm Real-Time Revel system, 274

Monitoring of glucose levels. See *Glucose monitoring*;  
*Glycemic control*.

Monitors/meters, blood glucose, 258t-264t

Mononeuropathies, 321t, 324

Monounsaturated fats, 52t, 54, 308t

Morbidity and mortality  
cardiovascular, diabetes and, 40. See also *Cardiovascular risk*  
of diabetes, 17  
reduction with early detection and treatment, 17, 312-313  
fetal, gestational diabetes and, 35  
macrovascular, in PROactive Study, 93-97, 95  
perinatal, postprandial hyperglycemia and, 65  
postprandial hyperglycemia and, 65  
in Steno-2 Trial, 70

Mortality. See *Morbidity and mortality*.

Muscular dystrophies, diabetes secondary to, 30t

Myalgia, in diabetic ketoacidosis, 282t

MyGlucoHealth Wireless blood glucose meter, 261t

Myocardial infarction  
β-blockers and, 303  
bromocriptine mesylate and, 154, 155  
diabetes as risk equivalent, 40  
incidence in newly diagnosed diabetics, 16  
pioglitazone and, 93-97, 95  
in trials and studies  
ACCORD trial, 71, 71  
PROactive Study, 93-97, 95, 101  
Steno-2 Trial, 70  
UKPDS, 67, 67t

Nasopharyngitis, 113, 125, 134

Nateglinide (Starlix), 77t, 145-148  
action mechanism, 145-146  
combination therapy with metformin, 142-143, 143, 145, 147  
dosage, 77t, 146-147  
glycemic control with, 143, 146, 147  
indications for, 145  
monotherapy, 142-143  
in NAVIGATOR trial, 344  
prescribing considerations, 146-147

Nateglinide (Starlix) (*continued*)  
side effects, 147-148  
vs metformin, 146, 147  
vs repaglinide, 142-143, 143

National Center for Chronic Disease Prevention and Health Promotion, 353

National Cholesterol Education Program (NCEP)  
guidelines, 41-44  
on diabetic dyslipidemia, 44, 305-308  
on LDL and HDL levels, 41-44  
on treatment/diagnosis of metabolic syndrome, 44  
on treatment/prevention of CHD, 41

National Diabetes Education Initiative (NDEI), 356

National Diabetes Education Program (NDEP), 356

National Eye Institute (NEI), 356

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 345, 357

National Kidney Foundation, 357

Native Americans. See *American Indians*.

Natural history of type 2 diabetes, 23-26, 24, 161

Nausea and vomiting  
with bromocriptine mesylate, 153, 154  
in diabetic ketoacidosis, 280, 282t  
with exenatide, 199  
in gastroparesis, 324  
with liraglutide, 221-222  
with pramlintide, 238-239

NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) trial, 344

NCEP. See *National Cholesterol Education Program*.

NDEI (National Diabetes Education Initiative), 356

NDEP (National Diabetes Education Program), 356

Nefazodone, 125

NEI (National Eye Institute), 356

Nelfinavir, 126

Nephropathy. See *Diabetic nephropathy*.

Nerve blocks, for painful diabetic neuropathies, 322, 323

Neurogenic bladder, 318, 321t, 326

Neurologic signs, in HHNS, 287-289

Neurontin (gabapentin), 322, 323

Neuropathy. See *Diabetic neuropathy*.

Neutral protamine Hagedorn (insulin). See *NPH*.

Niacin, in therapy for diabetic dyslipidemia, 309t

Niaspan, 311

Nicotinic acid  
for diabetic dyslipidemia, 309t, 310t, 311, 312  
secondary diabetes and, 30t

NIDDK. See *National Institute of Diabetes and Digestive and Kidney Diseases*.

Nifedipine, 304

Non-insulin-dependent diabetes. See *Type 2 diabetes mellitus*.

Nonpharmacologic treatment of type 2 diabetes, 47-62, 246.

See also *Exercise; Nutrition*.

Nonsteroidal anti-inflammatory drugs (NSAIDs), 322, 323

Nova blood glucose meters, 261t

Novo Nordisk, 292

Novolin 70/30 (NPH-insulin), 163, 182

regimens for, 183

time course of action, 167t

Novolog (aspart), 162, 182

for diabetic ketoacidosis, 285

time course of action, 164-165, 166t, 168

Novolog Mix

Novolog Mix 70/30, 163, 178, 182

plus MET, 183

time course of action, 167t

NPH, 163

for diabetic ketoacidosis, 285

disadvantages of, 179

dosage calculation for, 173t, 174t

hypoglycemia with, 177, 177

Novolin 70/30 (NPH-insulin), 184

regimens for, 169t

time course of action, 166t, 168

Treat-to-Target Study, 176-177, 176

vs detemir, 184-185

weight gain on, less, 188

NSAIDs, for painful peripheral neuropathies, 322, 323

Nutrition, 47-58. See also *Diet; Weight*.

alcohol intake, 52t, 57

assessment of food consumption/habits, 48

body weight considerations, 49-50, 50t

caloric intake, 51

carbohydrates in, 52t, 54-55

clinical trials involving, 337-340, 338t

exercise combined with, 44, 49, 63-64

fat intake, 52t, 53-54

fat substitutes, 56

fructose in, 55

goals of, 47

importance of, in therapeutic approach, 47

nutrient composition of diet, 51-57

nutrition consult (with dietitian), 48

nutrition therapy, 47-48

poor, diabetic ketoacidosis and, 279

protein intake, 52t, 53

recommendations for, 51-57, 52t

sucrose (sugar) intake, 52t, 55

suggested weights for adults, 49-50, 50t

sweeteners, nutritive/nonnutritive, 55-56

vitamin, mineral, and herb supplements, 52t, 56-57

Obesity. See also *Diet; Nutrition; Weight*.

central

metabolic syndrome and, 40, 44t, 45t

as risk factor for cardiovascular disease, 40

as risk factor for type 2 diabetes, 22, 34, 37

clinical trials involving obese patients, 338t, 339-340, 341

diabetes screening and, 345

fat intake, dietary, and, 52t, 53-54

hypoglycemia, reduced in, 188

as insulin-resistant state, 187

obese type 2 diabetes patients

HEELA study (exenatide vs insulin glargine), 199

insulin dosage for, 178

intensive insulin therapy in, 178-179

morbidly obese, insulin requirements, 179

pramlintide and, 237-238

SFUs and, 140

vs lean patients, 64

percentage of type 2 diabetics with, 49

as risk factor for diabetes, 13, 22, 24-25, 37

as risk factor for type 2 diabetes, 37

weight loss recommendations, 49-50, 50t

xenical and (XENDOS Trial), 338t, 341

Olestra, 56

Omega-3 fatty acids, in ORIGIN trial, 344

OneTouch blood glucose meters, 262t

Onglyza. See *Saxagliptin (Onglyza)*.

Ophthalmologist, referral to, 316t

Opium, tincture of, for diabetic diarrhea, 325

Oral agents for type 2 diabetes, 75-160, 76t-79t. See also *specific agents and classes of agents*.

in algorithm for treatment, 246-247

choice of, 75-80

classes of agents, 76t-79t

alpha-glucosidase inhibitors, 76t, 135-138

bile acid sequestrants (colesevelam), 76t, 148-152

dopamine receptor agonist (bromocriptine mesylate), 76t, 152-154

DPP-IV inhibitors, 76t, 102-135

glinides, 77t, 142-148

metformin (biguanide), 76t, 80-83

sulfonylureas, 77t, 138-141

thiazolidinediones (TZDs), 78t, 83-102

combination agents, 77t-78t

DPP-IV inhibitor/biguanide, 77t, 126

sulfonylurea/biguanide, 78t

thiazolidinedione/biguanide, 78t, 89-91

thiazolidinedione/sulfonylurea, 78t, 91-93

combination therapy, 246-247. See also *specific agents*.

contraindications, general, 80

dosage recommendations, 76t-79t

- Oral agents for type 2 diabetes (*continued*)
- as initial pharmacologic therapy, 75
  - concurrent with lifestyle changes, 75, 245
  - secondary failure of, 67, 68, 72-73
    - as indication for insulin therapy, 161
  - self-monitoring of blood glucose recommendation with, 268
  - specific agents
    - acarbose, 76t, 135-138
    - bromocriptine mesylate, 76t, 152-154
    - colesevelam, 76t, 148-152
    - linagliptin, 76t, 126-134
    - metformin, 76t, 80-83
    - migliitol, 76t, 138
    - nateglinide, 77t, 145-148
    - pioglitazone, 78t, 84-98
    - repaglinide, 77t, 142-148
    - saxagliptin, 76t, 115-126
    - sitagliptin, 76t, 102-115
    - sulfonylureas, 77t, 138-141
- Oral glucose tolerance test (OGTT)
- in diagnosis of diabetes, 38t, 39, 246
  - in diagnosis of IGT, 25
  - in screening of pregnant women, 35
- ORIGIN (Outcome Reduction With an Initial Glargine Intervention) study, 344
- Orinase (tolbutamide), 77t, 138
- Orlistat (Xenical), in XENDOS Trial, 338t, 341
- Orthostatic hypotension. See *Hypotension, orthostatic*.
- Osteoporosis, calcium supplements and, 52t
- Otitis, 295t
- Pacific Islanders, 16, 32, 37
- PAI-1 (plasminogen activator inhibitor-1), 93
- Painful neuropathies, treatment/management of, 322-323, 323
- Pancreatic disease, diabetes secondary to, 30t
- Pancreatic enzymes, in treatment of diabetic diarrhea, 325
- Pancreatic insulin secretion. See *Insulin secretion*.
- Pancreatitis, acute, sitagliptin and, 113-114
- Papaverine, 329
- Paresthesias, 291
- Pathophysiology of type 2 diabetes, 21-28
- as basis of pharmacologic therapy, 64-65
  - disease phenotype, 21-23
    - heterogeneity in, 23-24, 161-162
    - metabolic abnormalities, 21-23, 24, 64
  - natural history of diabetes, 23-26, 24
- Patient education
- about hyperglycemia and retinopathy, 313
  - about hypoglycemia, 170, 293
  - with Diabetes Warranty Program, 40, 42-43
  - in nutrition and diet, 48
  - in self-monitoring of blood glucose (SMBG), 55, 265
- Patient motivation, 40, 60, 245
- with self-monitoring of blood glucose, 265
- Patient self-monitoring of blood glucose. See *Self-monitoring of blood glucose*.
- PCI. See *Percutaneous coronary intervention*.
- Penile prostheses, 329-330
- Percutaneous coronary intervention (PCI), 70
- Peripheral atherosclerotic artery disease, 70
- Peripheral vascular disease, 298. See also *Macrovascular disease*.
- Peroxisome proliferator-activated receptors (PPARs), 83, 321
- PGC. See *Plasma glucose concentration*.
- Pharmacologic therapy for dyslipidemia, 308-312, 309t, 310t
- Pharmacologic therapy for type 2 diabetes, 63-74. See also *Oral agents for type 2 diabetes; Treatment of type 2 diabetes; and specific agents*.
- as adjunct to diet and exercise, 63-64
  - aggressive management, 63, 65-72
  - algorithm for, 243-245, 246-247
  - hyperglycemia, importance of controlling, 65, 66t
  - insulin therapy, 161-190
  - intensive therapy, 65-72, 168-170, 298
    - trials evaluating, 66-72
  - oral agents, 63, 75-160
    - secondary failure of, 67, 68, 72-73
  - overview of, 63-74
    - pathophysiologic basis of, 64-65
    - pramlintide therapy, 229-242
      - when to consider/initiate, 63-64, 73
- Phenotype B pattern, in diabetic dyslipidemia, 305
- Phenotype of type 2 diabetes, 21-23
- Phenoxybenzamine, for neurogenic bladder, 326
- D-phenylalanine derivative. See *Nateglinide*.
- Phenytoin
- for painful neuropathies, 322
  - secondary diabetes and, 30t
- Pheochromocytoma, diabetes secondary to, 30t
- Phosphate replacement
- in diabetic ketoacidosis, 284, 286
  - in HHNS, 290
- Phosphodiesterase-5 (PDE-5) inhibitors, 327-329, 328t
- Photocoagulation, laser, 316-317
- Physical activity. See *Exercise; Sedentary lifestyle*.
- Physical examination, 42-43, 59
- Pioglitazone (Actos), 78t, 84-98
- action mechanisms, 84, 101
  - cardiovascular risk and, 93-97, 95, 101
    - PROactive Study, 93-97, 95, 101
  - combination formulations, 78t, 85-90
    - with metformin (Actoplus Met/Actoplus Met XR), 78t, 86-87, 88t-89t, 97-98
    - with SFU-glimepiride (Duetact), 78t, 87-90, 91t, 92t, 98

- Pioglitazone (Actos) (*continued*)
- combination therapy, 85, 86
    - with linagliptin, 131-133, 133, 134
    - with saxagliptin, 121
    - with sitagliptin, 108-110, 110
  - dosage, 78t, 97-98
  - effects/benefits of
    - cardiovascular risk, 99
    - decreased insulin dose needed, 96-97, 96
    - effect on lipid levels, 90-93
    - fat distribution, 90
    - glycemic control, 85-90, 86, 95, 96
      - with combination agents, 87-90, 88t-89t, 91t, 92t
    - reduction in C-reactive protein, 93, 94
  - indications for, 84-85
  - monotherapy, 85-87, 86
  - prescribing considerations, 97-98
    - Actoplus Met, 97-98
    - Duetact, 98
  - safety and tolerability, 97
  - side effects, 98-101
    - CHF and edema, 99-100, 100t
    - liver toxicity, 98-99
    - weight gain, 90
  - trials and studies
    - ACT-NOW trial, 338t, 343-344, 343
    - PROactive Study, 93-97, 95, 101
    - TRIPOD, 341
  - vs metformin, 86, 97
- Plasma glucose concentration (PGC)
- in assessment of treatment, 249
  - as diagnostic criteria, 38t, 39
  - home monitoring of. See *Self-monitoring of blood glucose (SMBG)*.
  - measuring, 249-251
  - normal values, 38t
  - postprandial, 65, 66t
  - random testing, 39
  - target/goal values, 249t
  - testing for, 38-40, 38t
- Plasminogen activator inhibitor-1 (PAI-1) antigen, 93, 95
- PocketChem EZ monitoring system, 261t
- Podiatrists, 331
- Polycystic ovary syndrome
- as criterion for dysmetabolic syndrome X, 45t
  - diabetes secondary to, 31t
  - as risk factor for diabetes, 37
- Polydipsia
- in diabetes mellitus, 37, 80
  - in diabetic ketoacidosis, 281
  - in HHNS, 287
- Polyphagia, as symptom of diabetes, 37
- Polyunsaturated fats, 52t, 54
- Polyuria
- in diabetes mellitus, 37, 80
  - in diabetic ketoacidosis, 281
- Postprandial glucose (PPG), 29, 64-65, 243. See also *Hyperglycemia, postprandial*.
- AACE guidelines for control of, 65, 66t
- amylin and, 230-232, 232
  - gastric emptying and, 65, 232-233, 232
  - importance of controlling, 65
  - insulin control of, 232
  - normal levels, 235, 244t
  - specific agents and
    - acarbose, 135
    - alpha-glucosidase inhibitors, 135-138
    - GLP agonists, 191-192, 195
    - liraglutide, 206
    - migliitol, 138
    - nateglinide, 145-146, 147
    - pramlintide, 234, 235, 236, 238
    - target levels, 66t, 244t, 250t, 298
- Postprandial hyperglycemia. See *Hyperglycemia, postprandial*.
- Potassium
- antihypertensive agents and, 300t, 302
  - channels, 142
  - dietary supplementation/restriction of, 56-57
  - replacement
    - in diabetic ketoacidosis, 284, 285-286
    - in HHNS, 290
- PPARs (peroxisome proliferator-activated receptors), 83, 321
- PPG. See *Postprandial glucose*.
- Pramlintide therapy, 229-242. See also *Amylin*.
- action mechanisms, 230-234, 232
    - centrally-mediated effects, 232, 232
    - food intake/satiety regulation, 231, 232, 233-234
    - gastric emptying, slowing of, 230, 232-233, 232
    - glucagon suppression, 231, 232, 233
  - clinical efficacy, 234-239
  - clinical practice study, 236, 238
  - glycemic control, long-term, 234-236, 237
  - postprandial glucose, 234, 235
  - combination therapy
    - with insulin, 229-230, 234, 235, 236, 237
    - with metformin, 230
    - with SFUs, 230
  - dosing, 239-241
  - glucose homeostasis and, 230-232, 232
  - hypoglycemia with, 239
  - practical tips for patient, 240-241
  - side effects/adverse events, 238-239, 240
  - synthetic human pramlintide (Symlin), 229

- Pramlintide therapy (*continued*)  
 tolerability, 238-239  
 weight-loss effects, 234, 237-238, 237
- Prandimet (repaglinide/metformin), 77t, 144-145
- Prandin. See *Repaglinide*.
- Pravastatin, 309, 310t
- Precision Xtra blood glucose meter, 262t
- Precose. See *Acarbose*.
- Prediabetes, 24, 337  
 insulin secretion in, 22, 23
- Pregnancy. See also *Gestational diabetes mellitus*.  
 eye exam during, 316t  
 folic acid supplements in, 52t  
 risk assessment/diagnosis of GDM, 35, 39-40  
 treatment choices in, 163, 246
- Prevalence of type 2 diabetes, 13-16, 14, 15, 32  
 definition of, 13
- Prevention of diabetes, 337-349. See also *Early detection and management*.  
 clinical trials. See also *Primary prevention trials, diabetes*.  
 primary prevention trials, 337-344, 338t  
 reduced diabetes risk in other trials, 345, 346t  
 exercise and, 59  
 need for/importance of, 17, 297-298, 337, 345-347  
 screening and, 345  
 summary of, 345-347
- Primary care provider  
 request for/review of SMBG data, 249, 254  
 routine medical evaluation, 40, 42-44, 59
- Primary prevention trials, diabetes, 337-344, 338t  
 ACT-NOW trial, 338t, 343-344, 343  
 Da Qing (IGT and Diabetes Study), 337-339, 338t  
 DPP (Diabetes Prevention Program), 338t, 339-340  
 DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) trial, 338t, 342  
 FDPS (Finnish Diabetes Prevention Study), 338t, 339  
 Indian DPP, 338t  
 STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus), 338t, 341  
 TRIPOD (Troglitazone in the Prevention of Diabetes) study, 338t, 340-341  
 XENDOS (Xenical in the Prevention of Diabetes Mellitus in Obese Subjects) Trial, 338t, 341
- PROactive Study, 93-97, 95, 101
- Procoagulant state, 41, 44, 63, 243
- Prodigy blood glucose meters, 262t
- Propoxyphene, in treatment of painful diabetic neuropathies, 322
- Prostaglandins, 329
- Protein. See also *Diet; Nutrition*.  
 high-protein diets, LDL cholesterol and, 53  
 intake recommendations, 53  
 restriction, for diabetic nephropathy, 320-321
- Proteinuria  
 antihypertensive drugs and, 300t  
 in diabetic nephropathy, 318, 319  
*Pseudomonas aeruginosa*, in ear infections, 295t
- Pump therapy (insulin), 169t, 180-181, 246
- Pyelonephritis, 294t
- Quality of life, impact of diabetes on, 279, 296
- Questran, 311
- Race/ethnicity  
 incidence of diabetes and, 16  
 prevalence of diabetes and, 13, 15, 32  
 risk for diabetes and, 23, 34, 37  
 screening for diabetes and, 345
- Ramipril, 345  
 in DREAM Trial, 338t, 342  
 in HOPE study, 346t
- Recombinant DNA technology, 184, 185
- ReliOn blood glucose meters, 263t
- Renal disease  
 antihypertensive agents, potential benefits of, 301t  
 glipizide and, 141  
 linagliptin and, 127, 134  
 nateglinide and, 147, 148  
 repaglinide and, 144  
 saxagliptin and, 125  
 sitagliptin and, 112-113, 114
- Renal function. See also *Diabetic nephropathy*.  
 excessive protein intake and, 53  
 monitoring, 249
- Renal insufficiency/failure, macrovascular disease and, 298
- Renal transplant, 318
- Repaglinide (Prandin), 77t, 142-148  
 action mechanism, 142  
 combination therapy  
 with acarbose or miglitol, 136, 144  
 fixed-dose combination (with MET; Prandimet), 77t, 144-145  
 with metformin, 142-143, 143  
 triple-combination (TZD/repaglinide/MET), 129, 136, 144  
 contraindications/cautions, 142  
 dosage, 77t, 144-145  
 glycemic control with, 142-143, 143  
 indications, 142, 144  
 monotherapy, 142-143, 143  
 prescribing considerations, 144-145  
 side effects, 144  
 vs nateglinide, 142-143, 143
- Resources and publications on diabetes, 351-357
- Respiratory complaints, in diabetic ketoacidosis, 281
- Retinal detachment, 315
- Retinopathy. See *Diabetic retinopathy*.

Rezulin (Troglitazone), 338t, 340-341  
 Rightest blood glucose meters, 263t  
 Risk factors, cardiovascular. See *Cardiovascular risk*.  
 Risk factors for diabetes, 13, 14, 25, 34, 37-38  
   clinical trials  
     primary prevention trials, 337-344, 338t  
     risk reduction in other trials, 345, 346t  
   DPP (Diabetes Prevention Program), 338t, 339-340  
     gestational diabetes mellitus as, 35  
 Ritonavir, 126  
 Rosiglitazone (Avandia), 78t, 84, 101, 342  
   combination formulations (Avandamet; Avandaryl), 78t, 84  
   combination therapy, 78t, 84, 121  
   dosage, 78t, 84  
   effect on lipid levels, 90-93  
   indications for, 84  
   risks and warnings, 84, 101  
   trials and studies  
     DREAM trial, 338t, 342  
     with liraglutide, 209-221, 210t-211t, 214, 220  
 Salt, dietary intake of, 52t, 299  
 Saquinavir, 126  
 Satiety, pramlintide therapy and, 233-234  
 Saturated fats, 52t, 54, 308t  
 Saxagliptin (Onglyza), 76t, 115-126  
   actions/potency of, 115  
   adverse events, 121-125  
   approval in United States, 102, 115  
    $\beta$ -cell function and, 119  
   combination agent with metformin XR (Kombiglyze XR), 77t, 126  
   combination therapy, 117-121  
     with glyburide, 119, 122t-123t  
     with metformin, 117-119, 118, 120t, 121  
     with TZDs (pioglitazone or rosiglitazone), 121, 124  
   contraindications/cautions, 125-126  
   dosage, 76t-77t, 125-126  
   glycemic control with, 115-121  
   hypoglycemia and, 125  
   indications for, 115  
   pharmacodynamics, 115  
   prescribing considerations, 125-126  
   renal impairment and, 125  
   tolerability, 121  
   trials and studies  
     combination trials, 117-121  
     long-term use, 121  
     monotherapy trials, 115-117, 116  
 Screening  
   for diabetes, 25, 37, 345  
     ADA/NIDDK position on, 345  
     cost-effectiveness of, 337, 345  
   Screening, for diabetes (*continued*)  
     gestational diabetes mellitus, 35, 39-40  
     risk factors prompting, 345  
     for diabetic nephropathy, 318-319  
     for IFG/IGT, 345  
     for lipid abnormalities, 305, 306t  
   Secondary diabetes mellitus, 30t-31t  
   Sedentary lifestyle  
     as risk factor for diabetes, 13, 22, 25, 34, 38, 59  
     as risk factor for macrovascular disease, 298  
   Seizures, hypoglycemia and, 291  
   Self-monitoring of blood glucose (SMBG), 253-277, 258t-264t  
     accuracy of, 254, 257  
     advances in, 272-277  
     advantages and disadvantages of, 256  
     blood glucose meters, 258t-264t, 272, 273-277  
     contact information for manufacturers, 266t-267t  
     comparison with lab samples, 257  
     continuous glucose monitoring systems, 273-277  
     dietary adjustments and, 55, 57  
     error range in, 257  
     exercise and, 60  
     hypoglycemia prevention and, 188, 255, 293  
     logbook, 269, 270-271  
     patient dosage adjustment via, 174, 174t, 269-272  
       algorithm form, 274-275  
       split-mixed regimen, 276t  
       techniques for premeal hyperglycemia, 268t  
     patient education in techniques for, 55  
     patient education/motivation with, 265  
     for patients not taking insulin, 265-268, 268t  
     for patients taking insulin, 268-269  
     reasons for performing, 254-255  
     recommendation for all diabetes patients, 257  
     recommended frequency of, 265  
     record sheet, 269, 270-271  
     systems for, 257, 258t-264t  
   Semmes Weinstein monofilaments, 330  
   Seven Plus blood glucose system, 274  
   Sexual dysfunction, 321t, 326-330  
     diagnosis of, 327  
     erectile dysfunction, defined, 326  
     medications causing, 327  
       antihypertensive agents, 300t  
     treatments, 327-330  
       intracavernosal injection, 329  
       Medical Urethral System for Erection (MUSE), 329  
       penile prostheses, 329-330  
       phosphodiesterase-5 (PDE-5) inhibitors, 327-329, 328t  
       side effects and cautions, 328-329  
       sildenafil (Viagra), 327-329, 328t

- Sexual dysfunction, treatments (*continued*)
- tadalafil (Cialis), 327-329, 328t
  - testosterone, 327
  - vacuum constrictor devices, 329
  - varденаfil (Levitra), 327-329, 328t
  - yohimbine HCl, 327
- SFUs. See *Sulfonylureas*.
- Sickle cell trait, 251
- Sidekick blood glucose meter, 263t
- Sildenafil (Viagra), 327-329, 328t
- Simvastatin, 309, 310t
- Sitagliptin (Januvia), 76t, 102-115
- adverse events, 113-114
    - pancreatitis, 113-114
  - approval in United States, 102
  - $\beta$ -cell function with, 108, 109
  - body weight and, 113
  - in combination or add-on therapy, 107-112
    - with glimepiride, 111
    - with glipizide, 110-111
    - with insulin, 112
    - with metformin, 107, 109, 112
      - fixed-dose formulation (Janumet), 77t, 114-115
    - with pioglitazone, 108-110, 110
    - triple combination (with MET and TZD), 103, 114
  - contraindications/cautions, 113-114
  - dosing, 76t, 114
    - for Janumet, 77t, 114-115
  - glycemic control with, 103-113, 104, 109
  - hypoglycemia and, 106, 112, 113
  - indications for, 102-103
  - as initial therapy, 103
  - pharmacology/pharmacokinetics, 103
  - prescribing considerations, 114
  - renal disease patients and, 112-113, 114
  - side effects, 106, 108, 113-114
  - trials and studies
    - combination or add-on therapy, 107-112, 109, 110
    - monotherapy, long-term efficacy, 106-107
    - monotherapy trials, 103-107, 104
    - vs metformin, 106
- Sitagliptin/metformin (Janumet), 77t, 114-115
- Skin infections, 294t
- Skin reactions, 139
- Sleep disturbances, 296
- SMBG. See *Self-monitoring of blood glucose*.
- Smoking, macrovascular disease risk and, 298
- Sodium
- dietary intake of, 52t, 299
  - hyponatremia, 139
- Solo V2 blood glucose meter, 263t
- Starlix. See *Nateglinide*.
- Statins, 69, 148, 309-311, 309t, 310t, 321
- contraindications/cautions, 311-312
- Statistics on Type 2 diabetes, 13-20
- Steatohepatitis (fatty liver), 98
- Steno-2 Trial, 69, 70
- STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus), 338t, 341
- Stress
- in development of diabetic ketoacidosis, 279-280
  - test, prior to exercise program, 59, 61t
- Stroke
- antihypertensive agents, potential benefits of, 301t
  - bromocriptine mesylate and, 154, 155
  - incidence in newly diagnosed diabetics, 16
  - in PROactive study, 93-97, 95, 101
  - in Steno-2 Trial, 69, 70
- Studies. See *Trials and studies*.
- Stupor, in diabetic ketoacidosis, 282t
- Sugar (sucrose) intake, 52t, 55
- Sugar alcohols, 56
- Sulfonylureas, 77t, 138-141. See also *specific drugs*.
- action mechanism, 138
  - alcohol intake and, 57, 139
  - in algorithm for treatment, 246
  - cautions and contraindications, 140, 141
  - combination agents
    - sulfonylurea/biguanide agents, 78t
    - thiazolidinedione/sulfonylurea agents, 78t
  - combination therapy
    - with bromocriptine mesylate, 153, 154
    - with colesevelam, 149-151, 151
    - with exenatide, 195, 196-198, 197t, 201, 203, 204
    - with insulin, 141
    - with linagliptin, 130-131, 132t, 134
    - with liraglutide, 206
    - with metformin, 78t, 80-81, 246
    - with pioglitazone (Duetact), 78t, 87-90, 91t, 92t, 98
    - with pramlintide, 230
    - with rosiglitazone, 78t, 84
    - with saxagliptin, 122t-123t
    - with sitagliptin, 103
  - dosage, 77t, 140, 141
    - of combination agents, 78t
    - in elderly, 140
    - once-a-day, 141
  - drugs in this category, 77t, 138-139
  - efficacy, 139, 141
  - first generation, 77t, 138
    - acetohexamide (Dymelor), 77t, 138
    - chlorpropamide (Diabinese), 77t, 138

Sulfonylureas, first generation (*continued*)

- tolazamide (Tolinase), 77t, 138
- tolbutamide (Orinase), 77t, 138
- hypoglycemia and, 139-140
- prescribing considerations, 140
- second generation, 77t, 139, 141
  - advantages of, 139, 141
  - glimepiride (Amaryl), 77t, 139, 141
  - glipizide (Glucotrol), 77t, 139, 141
  - glipizide, extended release (Glucotrol XL), 77t, 139, 141
  - glyburide (DiaBeta, Micronase, Glynase PresTab), 77t, 139, 141
- side effects, 139-140
- in UKPDS, 67-69

Supplements, dietary, 52t, 56-57

- in Steno-2 Trial, 69

Sweeteners, nutritive/nonnutritive, 55-56

Symlin. See *Pramlintide therapy*.

Symptoms of diabetes/type 2 diabetes, 37

Tachycardia, hypoglycemia and, 290

Tadalafil (Cialis), 327-329, 328t

Taking Control of Your Diabetes (TCOYD), 357

Telithromycin, 126

TENS (transcutaneous nerve stimulation), 322, 323

Testosterone, 327

Texas Diabetes Council, 245

Thiazide diuretics, 300t, 301t, 304

- impotence and, 327
- secondary diabetes and, 30t
- in Steno-2 Trial, 69

Thiazolidinediones (TZDs), 78t, 83-102. See also *Pioglitazone*.

- action mechanisms, 83, 84, 101
- in algorithm for treatment, 246
- cardiovascular risk and, 84, 100-101
- cardiovascular risk reduction with, 93
- combination agents, 78t, 84, 101-102
  - triple-combination (TZD/repaglinide/MET), 103, 114, 136, 144
- combination therapy
  - with acarbose, 136
  - with exenatide, 195, 198, 200-201
  - with glinides, 144
  - with insulin, 84
  - with liraglutide, 206
  - with metformin, 78t, 81, 84, 86-87, 246
  - with repaglinide, 144
  - with SFUs, 78t, 84, 87-90
  - with sitagliptin, 103, 108-110
- contraindications/cautions for, 84, 99, 100t
- dosage, 78t
- early treatment with, benefits of, 84, 101
- effect on lipid levels, 90-93

Thiazolidinediones (TZDs) (*continued*)

- efficacy, 83-84, 85-87
- as first-line therapy, 25
- insulin resistance, reduction with, 83-84, 101
- liver function, monitoring, 98-99
- PPARs and, 83
- in prevention of diabetes, 25
- risks and warnings, 84, 101
- rosiglitazone, 78t, 84, 101
- side effects, 98-99
  - CHF and edema, 99-100, 100t
  - CVD and mortality risk, 100-101
  - liver toxicity, 98-99
- summary on, 101-102
- Thin (lean) patients, 64
- Thrifty gene hypothesis, 16
- Tolazamide (Tolinase), 77t, 138
- Tolbutamide (Orinase), 77t, 138
- Tolinase (tolazamide). See *Tolazamide*.
- Tradjenta (linagliptin). See *Linagliptin*.
- Tramadol (Ultram), 322, 323
- Transcutaneous nerve stimulation (TENS), 322, 323
- Treat-to-Target Study, 176-177, 176, 185
- Treatment of type 2 diabetes. See also *Oral agents for type 2 diabetes; Pharmacologic therapy for type 2 diabetes; and specific agents*.
  - aggressive, 283-284, 298
  - benefits of, 25-26
  - algorithm for, 243-245, 246-247
  - assessment of treatment regimen, 249-278
  - diet and nutrition in, 47-58
  - disease progression and, 25-26, 170, 180
  - early. See *Early detection and management*.
  - GLP-1 analogues, 194-224
  - glycemic control with
    - importance of, 65, 230-232
    - intensive therapy for, 65-72, 168-170, 298
    - target levels/goals, 13, 66t, 69-70, 72, 250t
    - summary of, 244t, 245
  - goals of, 243, 250t
  - metabolic goals, 65, 66t, 244t, 250t, 298
  - individualized approach in, 243-245
  - initial, strategy for, 245, 246
  - insulin therapy, 161-190
  - intensive therapy, 65-72, 168-170
    - algorithm form for, 274-275
    - reduced complications with, 298
    - trials evaluating, 66-72, 297-298
  - in lean vs obese patients, 64
  - with metabolic syndrome, 44-45
  - multipronged approach to, 229
  - new paradigm in, 230-232

Treatment of type 2 diabetes (*continued*)

- nonpharmacologic, 47-62
  - pharmacologic concurrent with, 63-64, 245
- oral agents, 75-160
  - pharmacologic, overview, 63-74
  - pramlintide therapy, 229-242
  - secondary failure of, 67, 68, 72-73
  - treatment modalities, 243

Trials and studies, 337-345, 338t, 346t. See also *specific trials*.

- ACCORD, 69-70, 71, 71, 72
- ACT-NOW, 338t, 343-344, 343
- ADVANCE, 69-70, 71-72
- ALLHAT, 346t
- Candesartan and Lisinopril Microalbuminuria study, 303
- CAPP, 346t
- CARDS, 310t
- CARE, 310t
- Cycloset Safety Trial, 154, 155
- Da Qing, 337-339, 338t
- DAIS, 310t
- DCCT, 66, 245, 254-255, 297-298, 319
- diabetes primary prevention trials, 337-344, 338t
- DPP, 338t, 339-340
- DREAM trial, 338t, 342
- Early Treatment Diabetic Retinopathy Study, 316-317
- FDPS (Finnish Diabetes Prevention Study), 338t, 339
- HEELA study, 199
- Helsinki trial, 310t
- HOPE trial, 302, 346t
- HPS, 310t
- intensive therapy, 65-72
- LEAD (liraglutide), 208-221, 210t-213t, 214, 216t-219t, 220
- LIFE, 346t
- NAVIGATOR, 344
- ORIGIN, 344
- PROactive Study, 93-97, 95, 101
- Steno-2 Trial, 69, 70
- STOP-NIDDM, 338t, 341
- Treat-to-Target Studies, 176-177, 176, 185
- TRIPOD, 338t, 340-341
- UKPDS, 66-72, 66t, 67, 245, 255, 298, 302, 303, 319
- VA-HIT, 310t
- VADT, 70-71, 72
- VALUE, 346t
- WOSCOPS, 346t
- XENDOS, 338t, 341

Tricor. See *Fenofibrate*.

Tricyclic antidepressants, for painful neuropathies, 322, 323

Triglycerides

- colesevelam and, 151-152
- hypertriglyceridemia, 304, 312

Triglycerides (*continued*)

- linagliptin and, 134
- lowering, 309t
  - with diet, 54
  - with fibric acid derivative, 312
  - with pioglitazone, 90, 95
- in metabolic syndrome criteria, 44t
- risk levels for adult diabetic patients, 37, 306t
- target/goal levels, 250t, 306t
- testing for, routine, 249
- treatment of (Steno-2 Trial), 69

TRIPOD (Troglitazone in the Prevention of Diabetes) study, 338t, 340-341

Troglitazone

- in DPP study, 340
- TRIPOD study, 338t, 340-341

True2Go blood glucose meter, 263t

Truebalance blood glucose meter, 263t

Trueresult blood glucose meter, 263t

Truetrack blood glucose meter, 263t

Twin studies, 21, 32

Tylenol, for painful diabetic neuropathies, 322, 323

Type 1 diabetes mellitus, 29-32, 30t. See also *Diabetes mellitus*.

- age of onset, 29, 30t, 35
- amylin deficiency in, 230, 231
- diabetic ketoacidosis and, 280, 284
- differences from type 2 diabetes, 32, 177-178
  - classification problems with, 35-36, 161
- insulin-pump therapy for, 180-181
- late-onset (LADA), 181
- pramlintide for, 230

Type 2 diabetes mellitus, 30t, 32-33. See also *Diabetes mellitus*.

- age of onset, 16, 17, 30t, 32
- algorithm for treatment, 243-245, 246-247
- asymptomatic, 32-33, 37
- $\beta$ -cell failure in, 23, 230
- classification of, 30t, 32-33
  - problems with, 35-36
- diagnosis, 37-46, 38t, 246
- differences from type 1 diabetes, 32, 177-178
- heterogeneous nature of, 23-24, 161-162
- incidence, 16-19, 17, 18
- metabolic abnormalities in, 21-23, 24, 63, 64
- natural history, 23-26, 24
  - and progression of therapies, 161, 170, 180
- pathophysiology, 21-23
- pharmacologic treatment overview, 63-74
- prevalence, 13-16, 14, 15
- prevention of, 337-349
- resources and publications on, 351-357
- signs and symptoms of, 32-33, 37

Type 2 diabetes mellitus (*continued*)

statistics on, 13-20

transition to, 21-23, 22-23, 24, 34

prevention or delay with treatment, 34, 337, 345

undiagnosed, problems of, 14-16

TZDs. See *Thiazolidinediones*.

UKPDS (United Kingdom Prospective Diabetes Study), 66-72

cardiovascular risk reduction in, 67-69

diabetic retinopathy in, 14

drugs studied in, 302, 303

glycemic control benefits, 66-67, 67t, 68, 245, 255, 298

microvascular disease reduction in, 66, 67t, 245, 298, 302

prevention/delay of complications in, 245, 297-298, 319

secondary failure in, 67, 68, 72-73

Ultralente, 179, 186

Ultram (tramadol), 322, 323

Undiagnosed diabetes, 13, 14-16, 37

HHNS in, 286

United Kingdom Prospective Diabetes Study. See *UKPDS*.

Uremia, 252, 282

Urinary tract infection

diabetes and, 294t, 296

diabetic nephropathy and, 318, 319

saxagliptin and, 125

VA-HIT, 310t

Vacuum constrictor devices, in treatment of sexual dysfunction, 329

VADT (Veterans Affairs Diabetes Trial), 70-71, 72

Vagus nerve, 232

Valsartan, 320, 344, 346t

VALUE trial (valsartan), 346t

Vardenafil (Levitra), 327-329, 328t

Vascular disease, as risk factor for diabetes, 38. See also *Macrovascular disease*.

Veterans Affairs Diabetes Trial (VADT), 70-71, 72

Viagra (sildenafil), 327-329, 328t

Victoza. See *Liraglutide*.

Vision loss. See *Diabetic retinopathy*; *Eyes*.

Vitamins/vitamin supplements, 52t, 56-57, 69, 319

Vitrectomy, in treatment of diabetic retinopathy, 317

VLDL particles, 90, 304, 312

Vulvovaginitis, 294t

Warranty Program, Diabetes, 40, 42-43

WaveSense blood glucose meters, 263t-264t

Weight, 49-50, 50t, 299. See also *Obesity*.

in cardiovascular risk assessment, 249

diabetes screening and, 345

gain

with glimepiride, 215

Weight, gain (*continued*)

with insulin therapy, 178, 185, 187-188, 229

with pioglitazone, 90

with rosiglitazone, 342

with sulfonylureas, 139

goal levels, 50t

ideal/suggested, 50-51, 50t

caloric intake for, 51

loss or neutrality, 44, 49-50

benefits of, 49

caloric intake for, 51

DPP-IV inhibitors and, 135

exenatide and, 197t, 198-199, 201-205, 201t, 203, 205

exercise and, 44, 59, 60

glimepiride and, 141

GLP-1 therapy and, 193, 224

in hypertension treatment, 299

linagliptin and, 129, 133

liraglutide and, 208, 209, 213t, 215, 216t, 218t, 220-221

metformin and, 81

pramlintide and, 234, 237-238, 237

sitagliptin and, 113

in treatment for metabolic syndrome, 44

in type 1 diabetes, 29

in type 2 diabetes, 32, 80

macrovascular disease risk and, 299

monitoring, 249

overweight patients, clinical trials involving, 338t, 339-340, 341

as risk factor for diabetes/type 2 diabetes, 13, 22, 25, 34

Welchol. See *Colesevelam*.

World Health Organization (WHO), diabetes criteria, 33t

WOSCOPS (West of Scotland Coronary Prevention Study), 346t

XENDOS (Xenical in the Prevention of Diabetes Mellitus in Obese Subjects) trial, 338t, 341

Xenical in the Prevention of Diabetes Mellitus in Obese Subjects (XENDOS) Trial, 338t

Xenical (XENDOS trial), 341

Yeast infections, 37

Yohimbine HCl, 327